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Since the introduction of recombinant insulin in 1979 and thanks to the advances 
in pharmaceutical biotechnology, therapeutic proteins and peptides have gained 
significant importance in the treatment of many diseases and after they represent the 
only therapeutic option. However, such growing success is not devoid of potential 
pitfalls like short half-life, easy enzymatic degradation and immunogenicity. 
PEGylation, namely the attachment of polyethylene glycol (PEG) chain(s) to a 
bioactive molecule, is nowadays one of the most commonly used strategies to 
overcome the inherent limits of therapeutic proteins. 
The studies reported in this thesis are focused on the design and preparation of 
conjugates of therapeutic proteins and peptides with optimized polymeric carriers, in 
order to obtain improved performances in both pharmacokinetic and 
pharmacodynamic profiles of a conjugated biologic. The proteins and the peptide 
used are recombinant human granulocyte colony-stimulating factor (G-CSF), 
recombinant human growth hormone (hGH) and KR14, an anti-HIV triazole peptide 
(PT). G-CSF, hGH and KR14, owing to their low molecular weights, are rapidly 
excreted from the body and are subject to proteolytic degradation, resulting in low 
bioavailability and therefore requiring frequent administration schedule. 
The first part of this PhD thesis was focused on: i) transglutaminase-mediated 
conjugation of common non charged or new multicarboxylic PEGs to G-CSF, ii) 
characterization and stability studies of the conjugates, iii) pharmacokinetic studies 
in animals, to allow the comparison between the conjugates and with the reference 
G-CSF. In this study, the aim was to test multicarboxylic PEG derivatives for 
evaluating the contribution of negative charges on protein half-life prolongation 
thanks to the charge-selective property of the glomerular filtration barrier. 
PEGylation with high molecular weight PEGs, by increasing the hydrodynamic 
volume of a protein, decreases the glomerular filtration rate, but may constitute a 
steric hindrance and reduce the binding affinity between the therapeutic protein and 
its target. The charge selectivity concept of the glomerular filtration barrier can be 
exploited with the new polyanionic polymers, which with low molecular weights, 
can still extend the PK profile of the protein and achieve also a better preservation of 
protein activity. 
The investigated polyanionic PEG derivatives were i) H2N-PEG5k-(COOH)7, a 
heterobifunctional PEG that was derivatized on one end with β-glutamic acid units to 
contain 7 carboxyl groups and ii) H2N-PEG3.4k-b-PLE50, a linear polyanionic 
polymer that consists of a PEG linked to a PLE with the pendant ϒ-carboxyl groups 
of glutamic acid monomers. In addition to these two multicarboxylic PEGs, two 
classic uncharged PEGs with molecular weights of 5 kDa and 20 kDa were also 
used. After PEGylation, all the G-CSF-PEG conjugates were characterized by 
MALDI-TOF mass spectrometry, SDS-PAGE and circular dichroism and the 
pharmacokinetic studies were carried out in rats. 
The second part of this PhD thesis focused on the comparison of the biological 
activity (stimulation of somatic growth) of three hGH conjugates differing for the 
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polymeric carrier (multicarboxylic or neutral) and for the site of polymer 
conjugation. The aim of this study was to evaluate if the protein stability and the 
protein/receptor recognition were influenced by the site of conjugation of the 
polymer and to assess the impact of polyanionic carriers on the pharmacodynamic 
behaviour of the protein. 
Conjugation of the multicarboxylic polymer, poly(L-glutamic acid), resulted in an 
increase of the final negative charge of the conjugate. Based on the charge selectivity 
concept of glomerular filtration, polyanionic polymers having relatively low 
molecular weights may provide a half-life extension of a given protein, similar to 
that provided by higher molecular weight neutral polymers. Two different site-
specific mono-PEGylated forms of hGH were prepared exploiting an enzymatic 
PEGylation (PEG-Gln141-hGH) via transglutaminase (TGase) and a chemical N-
terminal PEGylation (PEG-Nter-hGH), using neutral 20kDa PEGs. Interestingly the 
conjugates showed an increased thermal stability and the ability to refold after 
thermal denaturation. 
The third monoconjugate of hGH was prepared by chemical N-terminal 
conjugation, using poly(L-glutamic acid) with 50 glutamic acid units and with an 
aldehyde function at one end (PLE50ald). The glutamic acid monomers confer to this 
polymer a polyanionic characteristic. hGH-PLE50ald was characterized by MALDI-
TOF mass spectrometry, SDS-PAGE, circular dichroism and the pharmacokinetic 
studies were carried out in rats. The bioactivities of a single dose of hGH-PLE50ald, 
PEG-Gln141-hGH and PEG-Nter-hGH were similar or even better to that of a daily 
injection of hGH, by testing the somatic growth in hypophysectomized rats. 
The third section of this work has dealt with: synthesis and characterization of 
KR14 peptide and its conjugation with PEG20kDa-Mal, pharmacokinetic studies of the 
conjugate in mice and SPR affinity binding experiments. A part of this work was 
developed at the Department of Biochemistry and Molecular Biology of the Drexel 
University College of Medicine in Philadelphia, under the supervision of Professor 
Irwin Chaiken, whose laboratory is focused on the design and realization of peptide 
drugs that inhibit the entry of HIV-1 in the target cells. This initial step of HIV-1 
entry is characterized by the binding of envelope glycoprotein gp120 on to the 
cellular receptor CD4 and co-receptor. The triazole peptide KR14 derive from a 
previously known family of PT’s that has great therapeutic potential as it exhibits 
high affinity binding to gp120 and inhibits interactions of gp120 with both CD4 and 
the co-receptor surrogate mAb17b. KR14 was designed to contain a free thiol group 
at position 16 that has been exploited to achieve selective PEGylation with a PEG-
maleimide of 20 kDa. The identity and purity of the conjugate were confirmed by 
SEC-HPLC and MALDI-TOF. Pharmacokinetic studies in mice demonstrated that 
PEGylation extended the t1/2 of the peptide from 44 min to 289 min. Even more 
remarkably the conjugate did not show the typical loss in bioactivity, common to 
most PEGylated drugs. In fact SPR studies demonstrated that PEG-KR14 is only 
about 1.5, 1.6 fold less active than KR14, a relevant result. In conclusion the studies 
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of this PhD thesis further demonstrated the potential of PEGylation in the delivery of 
protein and peptides. Although PEGylation is already a mature technology that 
yielded several products in clinical use, we demonstrated that there are still reasons 
for implementation and new discoveries by pursing also the renal filtration charge 
selectivity and not only the size selectivity as done so far in this field. 
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Sin dall’introduzione dell’insulina ricombinante, nel 1979 e grazie ai progressi 
della biotecnologia farmaceutica, proteine e peptidi terapeutici hanno raggiunto una 
significativa importanza nel trattamento di molte patologie e rappresentano l’unica 
opzione terapeutica. Questo crescente successo non è comunque, privo di potenziali 
ostacoli come una breve emivita, una facile degradazione enzimatica e 
l’immunogenicità. La PEGhilazione, ovvero il legame di catene di polietilenglicole 
(PEG) a molecole bioattive, è oggigiorno una delle più comuni strategie usate per 
superare i limiti inerenti alle proteine terapeutiche. 
Gli studi riportati in questa tesi di dottorato sono focalizzati sulla progettazione e 
preparazione di coniugati di proteine e peptidi terapeutici con carrier polimerici 
ottimizzati, in modo da ottenere migliori prestazioni dell’entità coniugata, sia dal 
punto di vista del profilo farmacocinetico che farmacodinamco. Le proteine e il 
peptide usati in questo lavoro sono G-CSF, o fattore di crescita umano ricombinante 
stimolante la formazione di colonie granulocitiche, hGH, o ormone della crescita 
umano ricombinante e KR14, un peptide anti-HIV. G-CSF, hGH e KR14, a causa del 
loro basso peso molecolare, sono rapidamente eliminati dall’organismo e sono 
soggetti a degradazione proteolitica, con conseguente bassa biodisponibilità e 
necessità di somministrazioni frequenti. 
La prima parte di questa tesi di dottorato è focalizzata su: i) PEGhilazione 
enzimatica via transglutaminasi di G-CSF a PEG non carichi e a nuovi PEG 
multicarbossilati, ii) caratterizzazione e studi di stabilità dei coniugati ottenuti, iii) 
studi farmacocinetici in ratti, per avere un confronto tra i coniugati e la proteina 
nativa come riferimento. Lo scopo di questo studio è stato quello di testare i PEG 
multicarbossilati per valutare il contributo delle cariche negative sul prolungamento 
dell’emivita della proteina, grazie alle proprietà di selezione della carica della 
barriera di filtrazione del glomerulo. La PEGhilazione con PEG ad alto peso 
molecolare, aumentando il volume idrodinamico della proteina, riduce la velocità di 
filtrazione glomerulare, ma può costituire un impedimento sterico e ridurre l’affinità 
di legame tra la proteina terapeutica e il suo target. Il concetto di selettività della 
carica della barriera di filtrazione glomerulare può essere sfruttato con i nuovi 
polimeri polianionici, che, con un basso peso molecolare, possono mantenere un 
profilo farmacocinetico della proteina esteso e raggiungere anche una migliore 
conservazione dell’attività della proteina. I PEG polianionici usati per questo lavoro 
sono stati i) H2N-PEG5k-(COOH)7, un PEG eterobifunzionale che è stato 
derivatizzato ad un’estremità con unità di acido β-glutammico e che possiede 7 
gruppi carbossilici e ii) H2N-PEG3.4k-b-PLE50, un polimero polianionico lineare 
costituito da PEG legato a PLE, il quale possiede i gruppi pendenti ϒ-carbossilici dei 
monomeri dell’acido glutammico. Oltre a questi due PEG multicarbossilati, sono 
stati usati anche due PEG non carichi, di peso molecolare 5 e 20 kDa. Dopo 
PEGhilazione, tutti i coniugati di G-CSF sono stati caratterizzati tramite MALDI-
TOF, SDS-PAGE e dicroismo circolare e gli studi farmacocinetici sono stati condotti 
in ratti. 
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La seconda parte di questa tesi di dottorato si focalizza sul confronto dell’attività 
biologica (stimolazione della crescita somatica) di tre coniugati dell’ormone della 
crescita che si differenziano per il carrier polimerico (multicarbossilato o neutro) e 
per il sito di coniugazione del polimero. Lo scopo di questo studio è stato valutare se 
la stabilità della proteina e il riconoscimento proteina/recettore sono stati influenzati 
dal sito di coniugazione del polimero e verificare l’impatto di carrier polianionici sul 
profilo farmacodinamico della proteina. La coniugazione del polimero 
multicarbossilato, acido (poli)glutammico, risulta in un aumento della carica 
negativa netta del coniugato. Sulla base del concetto di selettività della carica della 
filtrazione glomerulare, polimeri polianionici aventi pesi molecolari relativamente 
bassi, possono fornire un’estensione dell’emivita di una proteina simile a quella 
ottenuta con polimeri neutri di alto peso molecolare. Due diverse forme di hGH 
mono-PEGhilato in maniera sito-specifica sono state preparate sfruttando una 
PEGhilazione enzimatica (PEG-Gln141-hGH) via tranglutaminase (TGase) e una 
PEGhilazione chimica all’N-terminale (PEG-Nter-hGH), usando PEG neutri di peso 
molecolare 20 kDa. Interessante è il fatto che i coniugati hanno mostrato una stabilità 
termica aumentata e la capacità di refold dopo denaturazione termica. 
Il terzo monoconiugato di hGH è stato preparato tramite coniugazione all’N-
terminale, usando un acido (poli)glutammico con 50 unità di acido glutammico e con 
una funzione aldeidica ad un’estremità (PLE50ald). I monomeri di acido glutammico 
conferiscono al polimero la caratteristica di polianionico. hGH-PLE50ald è stato 
caratterizzato tramite MALDI-TOF, SDS-PAGE, dicroismo circolare e gli studi 
farmacocinetici sono stati condotti in ratti. La bioattività di una dose singola di hGH-
PLE50ald, PEG-Gln141-hGH e PEG-Nter-hGH si è dimostrata simile o migliore 
rispetto a iniezioni giornaliere di hGH, misurando la crescita somatica in ratti 
ipofisectomizzati. 
La terza parte di questo lavoro tratta di: sintesi e caratterizzazione di KR14 e 
coniugazione di KR14 a PEG20kDa-Mal, studi farmacocinetici del coniugato in topi 
e studi di affinità di legame tramite SPR. Una parte di questo lavoro è stata 
sviluppata al Dipartimento di Biochimica e Biologia Molecolare presso Drexel 
University College of Medicine a Philadelphia, sotto la supervisione del Professor 
Irwin Chaiken, il cui laboratorio è focalizzato sulla progettazione e realizzazione di 
farmaci peptidici che inibiscono l’entrata del virus HIV-1 nelle cellule target. Questo 
passaggio iniziale di entrata del virus è caratterizzato dal legame della glicoproteina 
di membrana gp120 al recettore cellulare CD4 e al co-recettore. Il peptide KR14 
proviene da una famiglia già nota di peptidi, modificati con triazolo, che ha un 
considerevole potenziale terapeutico, esibendo alta affinità di legame per la gp120 e 
inibendo le interazioni di gp120 con CD4 e con il surrogato del co-recettore 
mAb17b. 
KR14 è stato progettato in modo da comprendere un gruppo tiolico libero in 
posizione 16, che è stato utilizzato per la PEGhilazione selettiva con un PEG-
maleimide di 20 kDa. L’identità e la purezza del coniugato sono state confermate 
Riassunto 
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tramite SEC-HPLC e MALDI-TOF. Gli studi farmacocinetici in topi hanno 
dimostrato che la PEGhilazione ha prolungato l’emivita del peptide da 44 minuti a 
289 minuti. Ancora più interessante, il coniugato non ha mostrato la tipica perdita di 
bioattività, comune alla maggior parte dei farmaci PEGhilati. Infatti gli studi SPR 
hanno dimostrato che PEG-KR14 è solo 1,5, 1,6 volte meno attivo di KR14, un 
risultato rilevante. 
In conclusione gli studi di questa tesi di dottorato hanno dimostrato ulteriormente 
il potenziale della PEGhilazione nella veicolazione di proteine e peptidi. Anche se la 
PEGhilazione è già una tecnologia matura che ha portato diversi prodotti in uso 
clinico, abbiamo dimostrato che ci sono ancora motivi per l’implementazione e le 
nuove scoperte, perseguendo anche la selettività di carica della filtrazione renale e 
non solo la selettività per dimensioni, come fatto finora in questo campo. 
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2.1 THERAPEUTIC PROTEINS 
 
The growing knowledge in disciplines such as molecular biology and proteomics, 
and the recent developments in biotechnology in the past few decades, have resulted 
in a great interest in biotechnological drugs and discoveries on the role and activity 
of new proteins. Many of these proteins might be involved in pathological 
conditions, might represent new targets for highly specific therapies, or might even, 
themselves, become new drugs. Furthermore, a considerable number of proteins as 
therapeutic agents are approved drugs, currently on the market and have had great 
success in treating various diseases that were not possible to treat with conventional 
drugs [1]. 
The high structural complexity and certain physico-chemical characteristics of 
proteins limit their use in therapy. Proteins are very sensitive to variations in 
temperature, pH, and ionic force and are easily degraded by microbial agents. 
Moreover the therapeutic application of a new protein is hampered by unexpected 
shortcomings and/or poor therapeutic outcomes. Among these potential limits it is 
possible to list rapid body clearance, immunogenicity, physical and chemical 
instabilities (e.g. aggregation, adsorption, deamination, clipping, oxidation, etc.), and 
enzymatic degradation. In particular, a short half-life in blood, common for proteins 
having a molecular weight below the kidney excretion threshold, is of itself a 
significant problem because is reflected in frequent administrations of therapeutics or 
in administrations at high doses, to reach the desired effect, thus also simultaneously 
aggravating side effects. 
Several tools for the development of better therapeutic proteins, can be exploited, 
such as genetic engineering [2], advanced protein formulation, and delivery [3]. 
Genetic engineering is strictly at the base of some delivery approaches like the 
expression of fusion or hyper-glycosylated proteins. Drug delivery systems (DDSs) 
are particularly promising in improving the in vivo efficacy of active molecules as 
they can prolong the in vivo half-life and protect the drug from enzymatic 
degradation, thus enhancing the in vivo bioactivity. Various drug delivery 
approaches have been proposed and investigated to overcome the over mentioned 
limitations, including incorporation into micro/nanoparticles, liposomes or hydrogels 
and chemical modification with small molecules or polymers. Among others, 
conjugation of polymers to proteins surface has been a successful technology. Either 
natural or synthetic polymers have been tested for this purpose, but only 
poly(ethyleneglycol) (PEG) resulted in conjugates of great therapeutic and clinical 
success and therefore is widely used for the delivery of therapeutic proteins. 
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2.2 PEGYLATION OF PROTEINS AND PEPTIDES 
 
PEGylation is defined as the covalent attachment of poly(ethylene glycol) (PEG) 
chains to bioactive molecules. This technique has become the leading approach for 
overcoming most of the aforementioned limits of biologics and the number of 
PEGylated products on the market is continuously increasing, together with the 
number of new conjugates entering clinical trials [4]. 
 
 
2.2.1 Characteristic of polymeric carrier 
 
Several polymers of natural and synthetic origin have been studied. This resulted 
in the identification of requirements for an ideal carrier: 
 
 the polymer must be biocompatible and not induce significant toxicity or 
immunogenicity; 
 must be biodegradable by hydrolytic or enzymatic activity or have a 
molecular weight below the kidney excretion threshold; 
 posses a low polydispersity; 
 must be found in large-scale, low cost and made by simple economic 
processes; 
 must be hydrophilic; 
 must possess the functional groups that allow binding of the drug. 
 
 
2.2.2 Poly(ethylene glycol) (PEG) 
 
PEG is a synthetic and amphiphilic polymer composed of repeated oxyethylene 
units with molecular weight of 44 Da (figure 2.1). 
 
 
 
Figure 2.1: Structural formula of PEG. 
 
PEG is synthesized by anionic ring opening polymerization of ethylene oxide, 
initiated by nucleophilic attack of an anion on the epoxide ring. The three phases of 
the synthesis of PEG, shown in figure 2.2, are as follows: 
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I. Initiation: it begins with the nucleophile attack of OH- to ethylene oxide 
cyclic opening the epoxy ring and the formation of oxygen reactive alcohol; 
II. Propagation: the reaction propagation continues with the addition of other 
ethylene oxide molecules; 
III. Termination: the reaction is stopped by the action of a terminator. 
 
 
 
Figure 2.2: Synthesis of PEG. 
 
The initiator anion (RO
-
) can be a hydroxide (OH
-
) or methoxide (CH3O
-
); the 
former results in the formation of a bifunctional diol, whereas the latter results in the 
formation of a monomethoxy PEG (figure 2.3). The main advantage of 
monomethoxy PEG (mPEG) is the presence of only one functional group, preventing 
the cross-linking phenomenon. For polypeptide modification, mPEG is widely 
applied because of its negligible in vivo toxicity and ease of activation. 
 
 
 
Figure 2.3: Structural formula of PEG. 
 
Appropriate modulation of the polymerization reaction allows the attainment of 
polymeric chains of different molecular weights (300-50000 Da) characterized by a 
low polydispersity index. Physical properties of the polymer depends on the average 
length of the chain: the polymer is in the liquid form when its molecular weight is 
below 1 kDa, and in the solid form when above 1 kDa. 
PEG is a polymer suitable for bioconjugation thanks to many characteristics: is 
non-toxic, biocompatible, non-antigenic, and non-immunogenic. It is soluble in 
water and many organic solvents such as dichloromethane, chloroform, and benzene, 
whereas insoluble in ethanol and hexane. Being a non-biodegradable polymer, it 
must be used at molecular weights below 40 kDa to avoid body accumulation and it 
is available in the market in a wide range of molecular weights and structures at low 
cost. These characteristics allow the use of PEG in various applications in 
biomedical field. It has been approved by the American Food and Drug 
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Administration (FDA) as a constituent of food, cosmetic products and 
pharmaceutical formulations.  
Moreover, PEG has a great capacity of coordinating water molecules, allowing to 
increase its hydrodynamic volume up to 5-10 fold. The glomerular filtration limit for 
PEG, therefore, is not 66 kDa as it is for proteins, but is 20 kDa. Consequently, 
elimination of PEGs having molecular weights greater than 20 kDa is mainly via 
biliary route. PEGs of molecular weights higher than 40 kDa should not be used, as 
PEG is not biodegradable and would accumulate in the body. 
 
 
2.2.3 Advantages of PEGylation 
 
PEG is one of the most commonly used polymers in the field of drug delivery, 
due to its physico-chemical characteristics such as high flexibility, hydrataion, and 
biocompatibility. PEGylation of therapeutic proteins results in conjugates with 
improved physico-chemical and pharmacokinetic characteristics. 
Among the main advantages of therapeutic protein PEGylation are: 
 
 reduction of the rapid kidney clearance of the PEGylated protein by 
increasing its hydrodynamic volume, 
 protection from chemical and enzymatic degradation, due to the masking of 
amino acid sequences or critical sites that are sensitive to degradation,  
 prevention of immunogenicity, by masking of critical sites recognized by 
antibodies, 
 increasing of thermal stability of proteins [5], 
 reduction of protein aggregation owing to a repulsion between PEGylated 
surfaces [6] 
 reduction of administration and dosages (Figure 2.4) 
 
 
 
Figure 2.4: Interferon and PEG-IFN-2a administration. 
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Many studies on this technology report that the secondary and tertiary structures 
of the conjugated proteins were unchanged after PEGylation [7, 8]. Nevertheless, a 
reduction in biological potency is usual after PEGylation due to the steric 
entanglement of polymer chains during protein/receptor recognition process. 
 
 
2.2.4 Chemistry of PEGylation 
 
A linear PEG derivative, used for PEGylation, has two unique ends. For the 
coupling of PEG to a molecule (i.e. proteins, peptides), it is necessary to activate the 
PEG through derivatization with a functional group at one or both ends. The choice 
of the functional group depends on the available target reactive group on the 
molecule to be PEGylated. The most commonly selected PEGylation sites in proteins 
are N-terminal amino group or the ε-amino group of lysines and thiol group of 
cysteines, due to their relatively high chemical reactivity under mild conditions with 
respect to other amino acid residues. 
Various PEG derivatives used for PEGylation reactions are as follows: 
 
 PEG derivatives reactive towards amino groups: include alkylating PEGs 
(Figure 2.5) which result in the formation of a secondary amine upon 
coupling to a protein and acylating PEGs such as PEG-carboxylates (Figure 
2.6) and PEG-carbonates (Figure 2.7) that generate amides or urethanes. 
 PEG derivatives reactive towards thiol groups: include PEG–
pyridildisulphide, PEG–maleimide, PEG–vinylsulfone, and PEG–iodo 
acetamide (Figure 2.8). 
 
 
 
Figure 2.5: Alkylating PEGs. 
 
Chapter 2 
 
 20 
 
 
Figure 2.6: PEG-carboxylates. 
 
 
 
Figure 2.7: PEG-carbonates. 
 
 
 
Figure 2.8: Thiol reactive PEGs. 
 
Recently, PEGs having particular structures and/or functions have been designed 
to improve the characteristics of the bioconjugates, including branched, dendritic and 
multi-arm PEGs. Figure 2.9 demonstrates several different PEG structures.  
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Figure 2.9: Various PEG structures [9]. 
 
 
2.2.5 PEGylation strategies 
 
An ideal PEGylation strategy must ensure the preservation of protein’s biologic 
activity to a high extent and this can be achieved by coupling the polymer to the 
amino acid residues that are not essential for the biological activity of the protein or 
the peptide. Moreover, it should shield the amino acid sequences that are subject to 
proteolytic degradation and those that are epitopes for antibodies. To this extent, the 
important parameters to take into consideration for PEGylation of therapeutic 
proteins and peptides are the molecular weight of PEG to be used, the type of its 
activating group and the conjugation method. 
 
 
Figure 2.10: Drawing of amino acids and sites in a protein that can be modified by 
PEGylation. 
 
Several FDA-approved PEGylated therapeutic proteins currently in the market are 
products of non-specific conjugation. Amine PEGylation, where the polymer is 
coupled to the ε-amine of lysine residues, is the most widely used technique among 
the non-specific ones. Due to the abundance of lysine residues in proteins, however, 
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this technique has low selectivity and results in complex mixtures with different 
degrees of PEGylation, compromising the bioactivity of proteins. The final product, 
given its heterogeneity, is relatively hard to purify and characterize. More recently, 
with the aim of overcoming these limitations, researchers have developed site-
specific PEGylation techniques including N-terminal PEGylation, thiol PEGylation, 
bridging PEGylation, and enzymatic PEGylation. In figure 2.10, the different sites of 
PEGylation are shown. 
 
 
N-terminal PEGylation. N-terminal PEGylation takes advantage of the different 
pKa values between the ε-amino residue of lysines, about 9.3–9.5, and the α-amino 
group at the protein N-terminus, about 7.6–8. In mildly acidic conditions (pH 6–6.5) 
the reaction at the N-terminus is selective because, at that pH, the ε-amino groups are 
protonated and consequently no reactive toward PEGylating agents while the α-
amino group is still partially present as free base and available for the coupling 
reaction. Low-reactivity PEGylating agents such as PEG-aldehyde should be used 
for this type of conjugation, otherwise the polymer might be coupled to lysine 
residues as well. 
The conjugation reaction proceeds as follows (Figure 2.11): 
1. formation of a Schiff base intermediate (R1-N=CH-R2) between the aldehyde 
and N-terminal 
2. Reduction of the Schiff base to secondary amine with NaCNBH3 
 
 
 
Figure 2.11: Site-specific conjugation of PEG-aldehyde to protein N-terminal. 
 
Thiol PEGylation. Cysteine, in its reduced form, is rarely present in proteins 
because it is usually paired with another cysteine, forming a disulfide bridge. 
Proteins with a single free cysteine can be site-specifically PEGylated using a PEG 
derivative reactive toward this residue. Moreover, thanks to genetic engineering, 
thiol PEGylation is not limited only to those proteins having a free cysteine but can 
be virtually applied to any biologics. PEG maleimide is the most common used thiol 
reactive PEGylating agent. A thioether bond is formed by Michael's addition 
between the double bond of the maleimide ring and the thiol group of cysteine 
(figure 2.12). 
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Figure 2.12: Thiol PEGylation. 
 
Bridging PEGylation. Disulfide bridges are found in small numbers in 
therapeutic proteins, therefore can be considered for site-selective PEGylation. In 
this technique, a bifunctional PEGylating agent is linked to a reduced disulfide 
bridge in the protein. The scheme of reaction is shown in figure 2.12. 
 
 
Figure 2.12: Bridging PEGylation. 
 
Enzymatic PEGylation. Enzymes have been considered as tools for site-specific 
PEGylation of proteins, especially for coupling PEGs to amino acid residues that are 
usually not modified with chemical methods. Due to the high specificity and 
selectivity of the enzymes, the yield of the synthesis is generally high. Microbial 
transglutaminase (mTGase) and sortase A are among the enzymes that have been 
investigated for this purpose.  
 
 
2.2.5.1 mTGase-mediated PEGylation 
 
TGases are a large family of enzymes detected in several organisms, including 
mammals, invertebrates, plants and microorganisms [10]. These enzymes are widely 
distributed in most tissues and body fluids, including liver, hair follicles, epidermis, 
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prostate and blood and are thought to be involved in a variety of physiological 
functions. TGase(s) catalyze the acyl transfer between the γ-carboxamide group of a 
protein-bound glutamine (Gln) residue and an aliphatic primary amine, generally the 
ε-amino group of a lysine (Lys) residue [11] (Figure 2.13). A typical example of a 
TGase-catalyzed protein crosslinking reaction is the termination of bleeding in 
wound healing (blood coagulation) by factor XIIIa, an activated form of plasma 
TGase catalysing crosslinking between fibrin molecules [12]. 
 
 
 
Figure 2.13: Amide bond formation catalyzed by TGase [13]. 
 
Among all the types of TGase(s), the most useful is a microbial TGase derived 
from a variant of Streptomyces mobaraense (Figure 2.14). mTGase has a molecular 
weight of 37.9 kDa, a high reaction rate and consists of a compact domain with the 
Cys64, the residue essential for the catalytic activity, located at the bottom of a deep 
cleft [14] (Figure 2.15). 
 
 
Figure 2.14: Overall structure of microbial TGase. Side chain of Cys64 is presented with 
ball-and-stick model [15]. 
 
            
B A 
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Figure 2.15: A) Overall structure of mTGase. Region in yellow circle: active site. B) 
Structure around the active site of mTGase. The catalytic triad of mTGase (Cys64, Asp255, 
His274) is presented with red wire model. 
 
For protein PEGylation, an amino-derivative of PEG (PEG-NH2) can be used as 
an amino donor in a TGase-mediated reaction to covalently attach a PEG moiety to 
protein-bound Gln residues of proteins of clinical utility [16]. The key step for 
catalysis involves the interaction of a γ-carboxamide group of a Gln residue of a 
polypeptide substrate with the TGases active site, forming a reactive thioacyl-moiety 
at the level of the Cys64 residue and then reaction with an amino donor, thus leading 
to a new isopeptide amide bond. 
mTGase has been studied and employed for bioactive drug application and in 
particular for covalent binding of PEG to a pharmaceutical protein, where its 
glutamine (Gln) residue(s) serves as acyl donor and an amino-derivative of PEG 
(PEG-NH2) serves as acyl acceptor (Figure 2.16). mTGase-mediated PEGylation 
presents two important advantages: 
i) the modification of glutamine, a residue that otherwise cannot be modified 
with chemical methods, and 
ii) the obtainment of highly homogenous conjugate isomer mixtures because 
usually only one or two glutamines, of all those present in a protein, are a 
substrate for the enzyme. 
 
 
 
Figure 2.16: Site-specific enzymatic PEGylation via mTGase. 
 
The conjugation reaction occurs in a highly site-specific manner; even when the 
protein contains more than one glutamine residue, usually only one or two are the 
substrates for the enzyme. 
Mero et al [17] conjugated a monodisperse Boc-PEG-NH2 via mTGase to three 
model proteins containing 17, 11, and 6 Gln residues (human G-CSF, human growth 
hormone, and horse heart apomyoglobin, respectively) and identified the glutamine 
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residues that were covalently attached to PEG by mass spectrometry. The results 
showed that, mTGase-mediated PEGylation of these three model proteins led to the 
production of only mono- and bi-conjugates. 
Several studies have been conducted to investigate the substrate specificity of 
TGases and the results revealed that there is no obvious consensus sequence around 
the Gln residues modified by TGase [18]. Fontana et al [19] observed that there is a 
notable correlation between the sites of enhanced chain flexibility and the sites of 
TGase attack. They concluded that the main feature directing the site-specific 
modification of a protein-bound Gln residue by TGase in a globular protein, is the 
flexibility or local unfolding of the chain region encompassing that Gln residue. 
When only one glutamine residue of a protein is substrate for mTGase, the 
resulting conjugate is homogenous. However, if the protein to be PEGylated contains 
more than one Gln residue as substrate for mTGase, the reaction results in a mixture 
of isomers. In that case, the selectivity of mTGase can be further increased by 
performing the reaction in the presence of organic co-solvents that would modify the 
flexibility of the chain encompassing the substrate Gln residue [20]. The organic co-
solvent acts as structure modifier and changes the native folding of the protein, 
reducing the flexibility of some regions. If a Gln residue found in these regions is 
substrate for mTGase in physiological conditions, it would lose its accessibility to 
mTGase upon the conformation change. Only the formerly substrate Gln residues 
encompassed in regions that are not affected by the presence of the organic co-
solvent will be substrates for mTGase in these new conditions. 
This strategy has been successfully applied to two model therapeutic proteins, 
salmon calcitonin and human growth hormon, with ethanol used as organic co-
solvent. Both proteins, possessing two glutamine residues as mTGase substrate and 
therefore yielding a mixture of isomers when PEGylated via mTGase in 
physiological buffers, yielded pure mono-PEGylated isomers when PEGylated in the 
presence of ethanol as co-solvent. In the view of these findings, it can be concluded 
that mTGase is a good choice for the site-specific PEGylation of therapeutic 
proteins. 
 
In this PhD thesis the PEGylation strategies used for the synthesis of the discussed 
conjugates were enzymatic PEGylation via mTGase, N-terminal PEGylation and 
thiol PEGylation. 
 
 
2.3 MULTICARBOXYLIC POLYMERS FOR THE DELIVERY OF 
PROTEINS 
 
 
PEGylation lead to a great improvement of the PK profile of a given protein but 
usually also a reduction in biological potency after modification, due to the steric 
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entanglement of polymer chains during recognition of the protein with its target. 
Although the reduction of the binding affinity is counterbalanced by a large 
improvement of the systemic exposure, site-selective conjugations strategies have 
improved the retention of the biologic activity. Moreover, the use of new PEGylating 
agents (polyanionic PEG) of low molecular weight should minimize the loss of 
biologics potency and allow the same systemic exposure obtained with neutral and 
higher molecular weight PEGs. 
 
 
2.3.1 Influence of ionic charge on glomerular filtration 
 
Proteins are eliminated from the body mainly by renal excretion. The glomerular 
filtration rate of low molecular weight molecules is higher compared to that of high 
molecular weight ones, and this phenomenon is responsible for the short plasma half-
life of therapeutic proteins. However, glomerular filtration rate does not depend only 
on the dimension of the proteins, but also on their ionic charge. It has been 
demonstrated that macromolecules, such as proteins, show a different elimination 
profile if they are charged [21]. 
The glomerular filtration barrier is composed of three layers: the fenestrated 
endothelium, the podocyte foot processes with bridging slit diaphragms and the 
intervening glomerular basement membrane (figure 2.17) [22]. The glomerular 
basement membrane consists of high-molecular weight proteins, including type IV 
collagen, laminins, entactin/nidogen, and sulfated proteoglycans. The major 
extracellular matrix-sulfated proteoglycans are collagen XVIII, perlecan, and agrin, 
all including heparin sulfate and chondroitin sulfate glycosaminoglycan chains. 
These chains, due to having sulfate radicals, impart negative charge on the 
glomerular basement membrane, and provide it with charge selective properties 
besides size-selectivity [23]. 
Negative charge associated with the glomerular filtration barrier is thought to 
retard filtration of anionic molecules due to repulsion [22]. This characteristic can be 
benefited to design new protein delivery systems using polyanionic polymers. 
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Figure 2.17: The glomerular filtration barrier and the concept of charge selectivity. 
 
 
2.3.2 Multicarboxylic polymers 
 
Multicarboxylic polymers bear on their structure carboxylic groups –COOH that 
confer the polyanionic characteristic to the polymeric backbone. PEG-dendron and 
poly(L-glutamic acid) (PLE) are among the examples of polyanionic polymers. 
PEG dendron (Figure 2.18) is characterized by a heterobifunctional PEG chain. At 
one end it is derivatized with a symmetric bicarboxylic unit such as β-glutamic acid, 
which provides the polymer with a branched structure with negative charges. The 
other end of the heterobifunctional chain may be derivatized with a functional group 
suitable for the conjugation method to be employed. 
 
 
 
Figure 2.18: PEG-dendron structure. 
 
PEG-dendron, H2N-PEG5k-(COOH)7, was synthetized starting from Boc-NH-
PEG5k-NHS of 5003 Da where, at one end, the amino group was protected with t-
Boc. After the removal of the protecting group to obtain the free amino group, the 
polymer was used for enzymatic PEGylation via tranglutaminase. 
 
PLE (Figure 2.19) is a natural polymer obtained by polymerization of β-glutamic 
acid, with the formation of peptide bonds. PLE, therefore, is biodegradable and non-
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toxic. It has a linear structure with a pending ϒ-carboxyl group for each repeated 
glutamic acid unit, conferring the polymer a polyanionic characteristic. The 
carboxylic groups, negative charged in phisiological condition, confer the solubility 
to the polymer. Moreover, the polymer has a ordered α-helical structure at pH lower 
than 5, while at higher pH, the ordered structure is converted in a random one. 
 
 
 
Figure 2.19: PLE structure. 
 
The PLE used in this thesis has 50 glutamic acid units (MW 6726 Da) and an 
aldehyde function at one end, protected by an acetal group. After removal of the 
protecting group, the polymer was used for N-terminal conjugation via aldehyde. 
 
The third used multicarboxylic polymers was H2N-PEG3.4k-b-PLE50, a linear 
polyanionic polymer that consists of a PEG of 3.4 kDa linked to PLE made up of 50 
L-glutamic acid units (Figure 2.20). Also in this case, the amino group suitable for 
enzymatic PEGylation, was initially protected by t-Boc. 
 
 
 
Figure 2.20: PEG-PLE structure. 
 
 
2.3.3 Multicarboxylic polymers for the delivery of Granulocyte-Colony 
Stimulating Factor and human Growth Hormone 
 
PEGylation, by increasing the hydrodynamic volume of a protein, decreases its 
renal clearance rate. However, while improving the pharmacokinetic profile of the 
conjugate, it may constitute a steric hindrance and reduce the binding affinity 
between the therapeutic protein and its target. 
Therefore, in order to significantly improve the pharmacokinetic profile of 
proteins, polyanionic PEGs with lower molecular weights than those required with 
neutral PEGs may be considered as protein carriers, thus reducing the typical steric 
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hindrance of high molecular weight PEG that might impair the biological function of 
proteins. To this aim the new polyanionic polymers, previously described, can be 
taken into consideration for therapeutic protein delivery applications. 
Moreover, polyanionic carriers should have also an impact on the 
pharmacodynamic behaviour of the protein. Conjugation of multicarboxylic 
polymers result in an increase of the final negative charge of the conjugate. The 
possibility to obtain the same half-life prolongation with low molecolar weight 
negative polymer might allows: 
 
i) a faster diffusion of the conjugate into the tissues, thanks to the lower 
hydrodinamic volume of the polymer, 
ii) a better preservation of the binding affinity of the protein to its receptor, 
thanks to the lower steric hindrance provided by the polymer and  
iii)  a decrease of protein aggregation due to charge repulsion. 
 
 
2.4 G-CSF 
 
G-CSF is a hematopoietic growth factor of myeloid lineage that regulates the 
proliferation, differentiation, and survival of granulocytes. Granulocytes 
(neutrophils, eosinophils, and basophils) are important mediators of antimicrobial 
and inflammatory responses. They are produced in bone marrow, through a process 
known as granulopoiesis (figure 2.21), both in health and diseased state. The 
productive capacity of bone marrow can increase to at least 10-fold in response to 
stress conditions [24]. 
 
 
Figure 2.21: Granulopoiesis in humans. 
 
Neutrophils represent the major subset of granulocytes, comprising 50–75% of the 
total circulating leukocytes. They play a fundamental role in immune response to 
invading bacteria, fungi, protozoa, viruses and tumor cells [24]. G-CSF is central to 
the production of neutrophils and is responsible for the significant increase in 
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neutrophil production in response to stress conditions, such as infection or offensive 
acts compromising bone marrow function, including anti-cancer chemotherapy. 
Many tissues can produce G-CSF when appropriately stimulated with 
inflammatory mediators such as lipopolysaccharide (LPS), tumor necrosis factor 
(TNF)-α, interferon (IFN)-β, vascular endothelial growth factor (VEGF), interleukin 
(IL)-17 and IL-1, inducing expression in endothelial cells, macrophages, epithelial 
cells and fibroblasts [25]. Release of G-CSF into the bloodstream by tissues 
stimulates neutrophil production within the bone marrow. 
G-CSF has also been shown to have an important influence on the biological 
functions of mature neutrophils. It stimulates phagocytic and chemotactic activity of 
neutrophils, increases the production of reactive oxygen intermediates in response to 
bacterial peptides, and enhances antibody-mediated cellular cytotoxicity (ADCC) 
against antibody-coated tumor target cells [26]. 
Additionally, G-CSF has shown to induce hematopoietic stem cell mobilization. 
Under normal conditions, the vast majority of hematopoietic stem/progenitors cells 
(HSPCs) reside in the bone marrow. The number of HSPCs in the circulation can be 
significantly increased in response to a number of stimuli, including hematopoietic 
growth factors and environmental stress such as infection [27]. A number of 
chemokines and cytokines have been shown to enhance migration of HSPCs into the 
peripheral blood [28]. This process is called hematopoietic stem cell mobilization.  
 
 
2.4.1 Structure of human G-CSF 
 
Mature human G-CSF is an 18.8 kDa protein composed of 174 amino acids 
(figure 2.22), cleaved from a precursor of 207 amino acids. It contains two intra-
molecular disulphide bonds (Cys36-Cys42 and Cys64-Cys74) that are essential for 
proper folding and function, and one free cysteine residue (Cys17). Native human G-
CSF has a single O-glycosylation site (Thr133) that protects the protein from 
aggregation but does not play a role in the biological activity of the protein [29]. G-
CSF contains 17 glutamine (Q) residues.  
 
 
Figure 2.22: Aminoacid sequence of G-CSF. 
 
X-ray crystallography of G-CSF revealed a four-α-helical bundle structure with an 
additional short 310 helix (figure 2.23) [30]. 
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Figure 2.23: Ribbon representation of the structure of human G-CSF. Helical regions are 
colored in blue, coil regions in pink. 
 
 
2.4.2 Recombinant human G-CSF and its therapeutic use 
 
Recombinant human G-CSF (rhG-CSF) has been widely used as a therapeutic 
agent to treat chemotherapy-induced neutropenia in cancer patients, and to accelerate 
hematopoietic recovery following transplantation. More recently, it has also been 
employed to achieve hematopoietic stem cell mobilization for stem cell 
transplantation. 
Chemotherapy is frequently accompanied by hematopoietic side effects due to the 
myelosuppressive character of the drugs used. These side effects generally include 
neutropenia (accompanied by fever and possible infection) and, to a lesser extent, 
thrombocytopenia and/or anemia [31]. rhG-CSF treatment reduces the duration of 
neutropenia and enhances hematopoietic reconstitution, and has therefore been used 
for recovery from chemotherapy and bone marrow transplantation. 
Recombinant human G-CSF was approved by the Food and Drug Administration 
(FDA) for the first time in 1991, under the generic name filgrastim (brand name: 
Neupogen®), for use in chemotherapy-induced neutropenia. Filgrastim, produced in 
Escherichia coli by recombinant DNA technology, has the identical biological 
activity as the endogenous protein. It only differs from the endogenous G-CSF in that 
it contains an additional N-terminal methionine residue and is not glycosylated [32]. 
Another pharmaceutical analog of human G-CSF is lenograstim, which is produced 
in Chinese Hamster Ovary (CHO) cells, and is therefore glycosylated. 
Several filgrastim biosimilars are currently in the market and are widely used. 
Nevertheless, filgrastim is rapidly excreted from the body due to its low molecular 
weight and consequent rapid renal clearance. It is also subject to proteolytic 
degradation. These issues result in a short half-life in vivo (1.8 - 3.5 hours), requiring 
multiple injections during one cycle of chemotherapy in cancer patients. In order to 
prolong the plasma half-life of filgrastim by decreasing its renal excretion, cellular 
uptake and proteolysis, a PEGylated filgrastim (Pegfilgrastim) was developed. 
Pegfilgrastim, obtained by N-terminal-specific chemical conjugation of the protein to 
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a linear PEG of 20 kDa, has demonstrated a significantly prolonged half-life (15 to 
80 hours), and is currently in the market under the name of Neulasta®. Clinical 
studies have shown that the effect of a single subcutaneous injection of Neulasta®, 
administered once per chemotherapy cycle, is similar to that of daily administered 
filgrastim. 
Scaramuzza et al [33] conjugated a PEG of 20 kDa to glutamine 135 residue of 
filgrastim, site-specifically,  via microbial transglutaminase enzyme. The result was a 
new monoPEGylated filgrastim derivate, named BK0026. 
 
 
2.5 hGH 
 
hGH is a 22-kDa protein secreted by the pituitary gland. Somatotroph cells 
located in the anterior pituitary gland intermittently releases growth hormone (hGH), 
which has many physiological functions including growth promotion, protein 
synthesis, lipolysis and regulation of metabolic processes [34]. Although growth 
hormone has many biological functions, its major target organs are bone and muscle, 
promoting the growth of the bone and increasing the mass of the muscles [35]. 
hGH deficiency in children results in a condition called pituitary dwarfism, which 
is characterized by slowed long bone growth, younger facial features and sometimes 
a chubby body build. Puberty may come late or not at all in older children. It is 
estimated that 10,000–15,000 children in the United States have growth failure due 
to growth hormone deficiency [36]. 
 
 
2.5.1 Structure of hGH 
 
Human growth hormone is a single-chain polypeptide. It is non-glycosylated and 
consists of 191 amino acid residues (Figure 2.24). hGH has three methionine 
residues in positions Met14, Met125, and Met170, eight tyrosine residues, one 
tryptophan residue (Trp86), and two disulphide bridges (Cys53–Cys165 and 
Cys182–Cys189). hGH contains 17 glutamine (Q) residues. 
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       130        140        150        160        170        180  
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       190  
CRSVEGSCGF  
 
 
Figure 2.24: Aminoacid sequence of hGH. 
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The crystal structure studies have shown that hGH is a four helix bundle with two 
disulphide bonds which are located towards the C-terminal end of hGH (Figure 2.25) 
[37, 38]. 
 
 
Figure 2.25: X-ray crystal structure of hGH. 
 
Growth hormone has two binding sites (site 1 and 2) and binds to two growth 
hormone receptors in 1:2 complex and initiate intracellular signaling event through 
receptor homo-dimerization, which is critical for signalling (Figure 2.26) [39, 40]. 
After the signaling event, the entire receptor–ligand complex is internalized resulting 
in signal termination. 
 
 
Figure 2.26: 1:2 hGH complex with its receptors. 
 
 
2.5.2 Recombinant hGH and its therapeutic use 
 
Recombinant human growth hormone (Genotropin®) is widely used to treat short 
stature resulting from hGH inadequacy, Turner’s syndrome, and renal failure both in 
children and adults [41]. hGH is also used to treat metabolic complications of hGH 
deficiency in adults and wasting in AIDS patients. hGH is given as a daily 
subcutaneous injection due to its short half-life of 20–30 min. Rapid proteolysis and 
ligand–receptor internalization result in a short half-life. Therefore a long acting 
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growth hormone receptor (GHR) agonist with sufficient stability to be dosed weekly 
is a highly desirable alternative especially for young children. 
r-hGH is produced and commercialized by several large pharmaceutical 
companies such as Eli Lilly (Humatrope), Genentech (Nutropin), Pfizer 
(Genotropin), and Serono (Saizen, Serostim). It has also become available as a 
biogeneric product (Sandoz’s Omnitrope, Biopartners’ Valtropin, and Cangene’s 
Accretropin). 
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2.6 HIV-1 
 
 
2.6.1 Epidemiology of HIV-1 subtype 
 
HIV-1 is among the most genetically diverse viral pathogens described to date. 
Isolates can be divided into groups, subtypes, and circulating recombinant forms 
(CRFs) (Table 2.1). The group M viruses, which are the most widespread and 
account for approximately 99% of infections worldwide, can be further subdivided 
into nine distinct genetic subtypes, or clades. These clades show characteristic 
geographic localization, with clade B viruses dominating Europe, the Americas, and 
Australia, while clade C, which presently infects more people worldwide than any 
other clade, is most prevalent in southern Africa, China, and India. Despite the 
prevalence of subtype C, most of the antiretroviral drugs available to treat HIV-1 
have been developed in the Western world using in vitro studies of subtype B 
isolates. However, there is a growing body of evidence that the different subtypes, 
and in particular the subtype C viruses, have unique antigenic, infectivity, and 
replicative characteristics [42, 43]. 
 
Table 2.1:Distribution of HIV-1 virus subtypes and CRFs. 
 
 
 
2.6.2 Structure 
 
Human immunodeficiency virus type 1 (HIV-1), the major pathogen responsible 
for the AIDS pandemic, is among the most genetically diverse viral pathogens 
described to date. 
HIV-1 is composed by two strands of RNA, 15 types of viral proteins and a few 
proteins from the last host infected cell, all surrounded by a lipid bilayer membrane 
(figure 2.27). Together, these molecules allow the virus to infect cells of the immune 
system and force them to build new copies of the virus. Each of these molecule plays 
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a role in this process, from the first steps of viral attachment to the final process of 
budding. 
The genes of HIV, that encode at least for nine proteins, are located into a cone-
shaped coat. The capsid protein forms stable hexamers, which then assemble like 
tiles to form capsids. Moreover the nucleocapsid protein forms a stable complex with 
the viral RNA, to protect it [44, 45]. The encoded proteins are divided into three 
classes: 
 
1. The major structural proteins, Gag, Pol, and Env 
2. The regulatory proteins, Tat and Rev 
3. The accessory proteins, Vpu, Vpr, Vif, and Nef 
 
The viral enzymes, encoded by Gag gene, are: reverse transcriptase (RT), protease 
and integrase. The reverse transcriptase produce a DNA copy of the viral RNA 
genome, which is then used to build new viruses. Many of the drugs currently used 
are inhibitors of this enzyme. HIV protease is essential for the maturation of HIV 
particles as HIV proteins are formed by a long polypeptide which is cleaved in the 
proper functional proteins by HIV protease. Another class of drugs are protease 
inhibitors that are used also in combination with inhibitor of RT and integrase. The 
IN protein mediates the insertion of the DNA copy of the viral genome into the 
genomic DNA of an infected cell. 
The matrix protein forms a coat on the inner surface of the viral membrane and it 
play a central role when new viruses bud from the surface of infected cells. 
gp120 and gp41 are surface glycoproteins of enveloped viruses. They play critical 
roles in the initial events of viral infection, mediating virion attachment to cells and 
fusion of the viral and cellular membranes. Envelope glycoproteins are also major 
targets for the anti-viral immune response in infected hosts. 
 
 
Figure 2.27:HIV-1 virus structure. 
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gp120 and gp41 are two non-covalently associated subunits that are generated by 
proteolytic cleavage of a precursor polypeptide, gp160 [46, 47]. gp120 directs target-
cell recognition and viral tropism through interaction with the cell-surface receptor 
CD4 and one of several coreceptors (Figure 2.28) that are members of the chemokine 
receptor family [48]. The membrane-spanning gp41 subunit then promotes fusion of 
the viral and cellular membranes, a process that results in the release of viral contents 
into the host cell. 
 
 
 
Figure 2.28:HIV-1 tropism for coreceptors. 
 
 
2.6.3 Life cycle 
 
The main several steps of HIV life cycle (Figure 2.29) consist in: 
 
1. Receptor binding: HIV binds to receptors on the surface of a CD4 cell. 
2. Fusion: the HIV envelope and the CD4 cell membrane fuse, allowing HIV 
to enter the CD4 cell. 
3. Reverse Transcription: once inside the target cell, HIV releases the reverse 
transcriptase that converts the HIV RNA into HIV DNA. This conversion 
is necessary for the entry of HIV DNA into the nucleus. 
4. Integration: integrase allows HIV DNA to enter the nucleus of the host 
cell. Once inside, the HIV DNA is integrated to the genetic material of the 
cell. 
5. Transcription and Translation: the virus exploits the host cell for the 
production of the precursors of virus proteins. 
6. Assembly: protease cuts up the precursors in order to obtain the virus 
proteins, that combine with HIV RNA to form a new virus. 
7. Budding: the new viruses are released from the target cell. 
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Figure 2.29:HIV-1 life cycle. 
 
In particular, initial entry of HIV-1 into host cells is mediated by a sequence of 
interactions of the trimeric gp120/gp41 envelope (Env) protein complex with host 
cells (Figure 2.30). In the host cell entry process, these two proteins participate in a 
sequence of cell receptor interactions initiated by binding of gp120 to cell surface 
CD4. This binding event causes conformational rearrangements within gp120 that 
expose and stabilize a co-receptor binding site [49]. CD4 and consequent co-receptor 
binding result in further conformational changes in the spike assembly that expose 
fusogenic as well as initially cryptic helical domains of gp41 [50]. The gp41 domains 
participate in conformational rearrangement and cell attachment processes leading to 
virus-cell membrane fusion and introduction of a viral genome into the cell [51]. The 
various steps in viral entry are relevant targets for anti-HIV intervention. 
 
 
 
Figure 2.30: Interaction of trimeric envelope protein complex with host cell. 
 
A part of the work reported in this thesis was developed at the Department of 
Biochemistry and Molecular Biology of the Drexel University College of Medicine 
in Philadelphia, under the supervision of Professor Irwin Chaiken, whose laboratory 
is focused on the design and realization of peptide drugs that inhibit the entry of 
HIV-1 in the target cells. 
 
 
2.6.4 Triazole peptide KR14 
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KR14 derives from a family of peptide triazoles which have nanomolar 
affinity for HIV-1 envelope protein gp120, and inhibit the interactions of 
gp120 at both receptor CD4 and the coreceptor surrogate mAb 17b. These 
peptide was generated by modification of a central proline residue on a 12-mer 
peptide, denoted 12p1, which was originally identified as a micro-molar 
affinity gp120 binder from phage display library screening. It was found that 
the replacement of the central Pro residue by azido-Pro and it’s click 
conjugation with ethynylferrocene led to variants with several orders of 
magnitude greater affinity. The resulting peptide triazole binds to gp120 with 
1:1 stoichiometry, inhibit interactions at both the CD4 and co-receptor binding 
sites and are broadly active in neutralizing cell infection by virus subtypes 
from all major clades [52]. 
KR14 is formed by 15 amino acids with an hexanoic spacer between the 
glutamine and the cysteine amino acid (Figure 2.31).  
 
 
 
 
 
 
 
Figure 2.31: KR14 structure. 
 
The sequence is Arg-Ile-Asn-Asn-Ile-Azp-Trp-Ser-Glu-Ala-Met-Met-bAla-
Gln-Ahx-Cys-CONH2, where Azp is azidoproline and Ahx is the 1-amino 
hexanoic acid. 
The pharmacophore is formed by the first 7 amino acids. The internal 
sequence cluster of Ftp-Trp at position 6 is required for function. In particular, 
that sequence provides a spatially arranged aromatic cluster, while the N-
terminal extension of residues may establish hydrogen bonding interactions 
that help stabilize productive Env protein binding [53]. For this reason, the 
PEGylation was achieved at the free thiol group of the cysteine, that is far from 
the pharmacophore region. 
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3.1 MATERIALS 
 
Recombinant human G-CSF was provided by Sandoz GmbH (Kundl, Austria) in a 
buffer solution of 50 mM phosphate and 5% sorbitol pH 7.0. hGH was supplied by 
Fidia Farmaceutici (Abano Terme, Italy). BOC-NH-PEG5k-NHS was from Iris 
Biotech GmbH (Marktredwitz, Germany). BOC-NH-PEG3.4k-b-PLE50 and PLEald50 
were purchased from Alamanda Polymers, Inc. (Huntsville, Alabama, USA). 
mPEG5k-NH2, mPEG20k-NH2 and mPEG20k-aldehyde were purchased from NOF 
Corporation (Tokyo, Japan). Microbial TGase (mTGase) from Streptomyces 
mobaraensis was purchased from Ajinomoto Co. (Tokyo, Japan). β-Glutamic acid, 
2,4,6-trinitrobenzenesulfonic acid, Glycyl-Glycine, N-Hydroxysuccinimide (NHS), 
N,N-Dicyclohexylcarbodiimide (DCC), sodium sulfate anhydrous (Na2SO4), 
dichloromethane (CH2Cl2), sodium cyanoborohydride (NaBH3CN), trifluoroacetic 
acid (TFA), acetonitrile, methanol (MeOH), D2O, sinapic acid, triethylamine (Et3N), 
Fmoc-Osu, N,N'-diisopropylcarbodimmide (DIC), methanesulfonyl chloride, sodium 
azide, tetrahydrofuran (THF), ethyl acetate (EtOAc), pyridine, N,N'-
Diisopropylethylamine (DIPEA), ethynylferrocene, 2-ethanedithiol, thioanisole, 
piperidine and salts of analytical grade were purchased from Sigma-Aldrich Co. (St. 
Louis, MO, USA). Precast gels were from BIO-RAD (Hercules, CA, USA). 
Invitrogen Human G-CSF ELISA Kit was purchased from Life Technologies 
(Carlsbad, CA, USA). hGH ELISA kit was from Tema ricerca Srl (Bologna, Italy). 
Hypophysectomized male Sprague Dawley rats were purchased from Charles River 
Laboratories (Lecco, Italy). All Fmoc-protected amino acids and HOBt were 
purchased from Novabiochem. Rink amide resin was obtained from Applied 
Biosystems.  
 
 
3.2 ANALITICAL METHODS 
 
Spectrophotometer analysis were performed with an Evolution 201 
Spectrophotometer of Thermo Scientific (Waltham, USA). 
1
H-NMR spectroscopy 
was performed with Bruker 400 MHz spectrometer and NMR data were processed 
using the program Topspin (Bruker GmbH, Karlsruhe, Germany). Shimadzu 
analytical HPLC system was used with C18 Jupiter (Phenomenex, Torrance, CA, 
USA; 5 μm, 300 Å, 250 x 4.60 mm) reverse phase column for analytical 
characterization and purification of PEG-G-CSF conjugates or with Zorbax GF-250 
(Agilent Technologies, Palo Alto, CA; 4.6 × 250 mm or 9.4 × 250 mm 4 μm) size 
exclusion chromatography (SEC) columns for analytical characterization and 
purification of hGH-PLE conjugate. Centrifugation was carried out with Hettich 
Zentrifugen mod. MIKRO 200. The freeze-drying was performed with freeze-
Hetossic Heto Lab Equipment. The dialysis tubing have been provided by Del 
Chimica Scientific Glassware (Naples, Italy). Aqueous and organic solutions were 
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evaporated with Rotavapor mod. R II BÜCHI (Switzerland). SDS-PAGE analyses 
were performed with Electrophoresis Power Supply 300 (Pharmacia, Sweden). 
Circular dichroism analyses were carried out with Jasco J-700 spectropolarimeter 
equipped with a Peltier temperature control unit. Mass analyses were performed with 
AB SCIEX MALDI-TOF mass spectrometer (Bruker-Franzen Analytik, Bremen, 
Germany). Pharmacokinetic profiles of PEG-G-CSF conjugates and native G-CSF 
were analyzed using Invitrogen Human G-CSF ELISA Kit. Pharmacokinetic profiles 
of hGH-PLE conjugate and native hGH were analyzed using hGH ELISA kit. 
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3.3 SYNTHESIS OF NH2-PEG-(β-Glu)-(β-Glu)2-(β-Glu)4-(COOH)8 
 
 
Firstly the activation degree of Boc-NH-PEG5k-NHS was determined. Then, the 
first step will provide the reaction between Boc-NH-PEG5k-NHS and the NH2-group 
of β-glutamic acid (β-Glu). 
 
 
3.3.1 Determination of the activation degree of Boc-NH-PEG5k-NHS 
 
The degree of activation of Boc-NH-PEG5k-NHS was determined by using a 
spectroscopic assay based on the so-called Glycyl-Glycine (Gly-gly) test. In this 
procedure, the degree of PEG activation is determined by reacting an equimolar 
amount of Gly-Gly with the activated PEG, followed by performing a Snyder and 
Sobocinsky colorimetric assay of the unreacted dipeptide [54]. This assay uses 2,4,6-
trinitrobenzenesulfonic acid (TNBS), which reacts stoichiometrically with primary 
amino groups in an alkaline medium to give a trinitrophenyl derivative absorbing at 
420 nm (Figure 3.1). 
 
Figure 3.1: Reaction between 2,4,6-trinitrobenzensulfonic acid and a free primary amine 
group. 
 
To 1 mL of 2 mM Gly-Gly solution, 1 eq. (2 µmol, MW 5000 Da) of Boc-NH-
PEG5k-NHS was added and the mixture was left at room temperature under 
continuous agitation. The TNBS assay was performed in duplicate according to 
Table 3.1. The reactions were incubated for 30 min before reading the absorbance at 
λ = 420 nm using a UV–visible spectrophotometer. The percentage of activation of 
Boc-NH-PEG5k-NHS was calculated by using the following formula: 
% Activation = [1 - (AbsA - AbsB) / (AbsG - AbsB)] x 100% 
where AbsA is the absorbance of PEG reaction mixture, AbsG is the absorbance of 
Gly-Gly standard solution and AbsB is the absorbance of the blank solution. 
 
Table 3.1: Preparation of test solutions for the TNBS assay. 
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Blank PEG reaction mixture (A) Gly-Gly standard solution (B) 
20 µL of TNBS 20 µL of TNBS 20 µL of TNBS 
980 µL of borate pH 9.3 955 µL of borate pH 9.3 955 µL of borate pH 9.3 
 25 µL of sample A 25 µL of sample B 
 
 
3.3.2 Synthesis of Boc-NH-PEG-β-Glu-(COOH)2 
 
Boc-NH-PEG-β-Glu-(COOH)2 was obtained by forming an amide bond between 
the activated carboxyl group of PEG and the amino group of β-glutamic acid as 
reported in figure 3.2. 
 
 
 
Figure 3.2: Synthesis of Boc-NH-PEG-β-Glu-(COOH)2 
 
2 g (0.4 mmol) of Boc-NH-PEG-NHS (MW 5000 Da; 84% of activated 
carboxylic groups) was added to 176 mg (1.2 mmol) of β-Glutamic acid (βGlu) (MW 
147.1 Da; 3 equivalent in excess to activated -COOH groups of PEG), dissolved in 
20 mL of 0.1 M borate buffer/CH3CN (3:2) mixture pH 8.0. The reaction was left 
under stirring. After 5 h, the pH was adjusted to about 5 with HCl 0.2 N and the 
product was purified from the excess of βGlu by extractions with CH2Cl2 (6 × 200 
mL). The organic phase, dried over anhydrous Na2SO4, was concentrated under 
vacuum and dropped into 500 ml of cold diethyl ether under stirring. After 1 h at -
20°C, the precipitate of Boc-NH-PEG-β-Glu-(COOH)2 was filtered and dried under 
vacuum (yield: 1.75 g, 87 %). The absence of free βGlu was verified by TNBS test 
according to Snyder and Sabocinsky assay previously reported. 
 
 
3.3.3 Activation of carboxylic groups of Boc-NH-PEG-β-Glu-(COOH)2 
via NHS/DCC 
  
The carboxylic groups of Boc-NH-PEG-β-Glu-(COOH)2 were activated to 
succinimide ester with NHS/DCC as reported in figure 3.3. 
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Figure 3.3: Activation of carboxyl groups of Boc-NH-PEG-β-Glu-(COOH)2 
 
430 mg (2.1 mmol) of DCC (MW 206.33 Da; 3 equivalent in excess for each 
carboxyl groups) and 120 mg (1.04 mmol) of NHS (MW 115.09 Da; 1.5 equivalent 
in excess for each carboxyl groups) were added to 1.75 g (0.35 mmol) of Boc-NH-
PEG-β-Glu-(COOH)2 (MW 5035 Da), previously dissolved in 20 mL of anhydrous 
CH2Cl2,. The reaction was stirred at room temperature overnight. Then the mixture 
was filtered and dropped into 500 mL of cold diethyl ether. After 1 h at -20°C, the 
precipitate of Boc-NH-PEG-(β-Glu)-(NHS)2 was recovered by filtration and dried 
under vacuum (yield: 1.64 g, 90.5%). The degree of activation, determined according 
to Snyder and Sabocinsky assay, was 81.6%. 
 
 
3.3.4 Synthesis of Boc-NH-PEG-(β-Glu)-(β-Glu)2-(COOH)4 
 
Boc-NH-PEG-(β-Glu)-(β-Glu)2-(COOH)4 (Figure 3.4) was obtained in the same 
manner of Boc-NH-PEG-(β-Glu)-(COOH)2 (section 3.3.2). 
 
 
 
Figure 3.4: Synthesis of Boc-NH-PEG-(β-Glu)-(β-Glu)2-(COOH)4 
 
1.64 g (0.3 mmol) of Boc-NH-PEG-(β-Glu)-(NHS)2 (MW 5229 Da; 81.6% of 
activated carboxylic groups) was added to 226 mg (1.5 mmol) of β-Glutamic acid 
(βGlu) (MW 147.1 Da; 3 equivalent in excess to activated -COOH groups of PEG), 
previously dissolved in 16 mL of 0.1 M borate buffer/CH3CN (3:2) mixture pH 8.0. 
The reaction was conducted as explained in section 3.3.2 (yield: 1.3 g, 78.4%). 
 
 
Chapter 3 
 
 48 
3.3.5 Activation of carboxylic groups of Boc-NH-PEG-(β-Glu)-(β-Glu)2-
(COOH)4 via NHS/DCC 
 
The carboxylic groups of Boc-NH-PEG-(β-Glu)-(β-Glu)2-(COOH)4 were 
activated to succinimide ester with NHS/DCC as reported in figure 3.5. 
 
 
 
Figure 3.5: Activation of carboxyl groups of Boc-NH-PEG-(β-Glu)-(β-Glu)2-(COOH)4 
 
1.3 g (0.25 mmol) of Boc-NH-PEG-(β-Glu)-(β-Glu)2-(COOH)4 (MW 5293 Da) 
were activated with 608 mg (2.9 mmol) of DCC (MW 206.33 Da; 3 equivalent in 
excess for each carboxyl groups) and 170 mg (1.48 mmol) of NHS (MW 115.09 Da; 
1.5 equivalent in excess for each carboxyl groups) and Boc-NH-PEG-(β-Glu)-(β-
Glu)2-(NHS)4 were recovered as reported in the section 3.3.3. The degree of 
activation was 83.5% (yield: 1.22 g, 88%). 
 
 
3.3.6 Synthesis of Boc-NH-PEG-(β-Glu)-(β-Glu)2-(β-Glu)4-(COOH)8 
 
Boc-NH-PEG-(β-Glu)-(β-Glu)2-(β-Glu)4 (COOH)8 (Figure 3.6) was obtained in 
the same manner of Boc-NH-PEG-(β-Glu)-(COOH)2 (section 3.3.2). 
 
 
 
Figure 3.6: Synthesis of Boc-NH-PEG-(β-Glu)-(β-Glu)2-(β-Glu)4 (COOH)8 
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1.22 g (0.2 mmol) of Boc-NH-PEG-(β-Glu)-(β-Glu)2-(NHS)4 (MW 5681 Da; 
83.5% of activated carboxylic groups) was added to 316 mg (2.15 mmol) of β-
Glutamic acid (βGlu) (MW 147.1 Da; 3 equivalent in excess to activated -COOH 
groups of PEG), previously dissolved in 12 mL of 0.1 M borate buffer/CH3CN (3:2) 
mixture pH 8.0. The reaction was conducted as explained in section 3.3.2 (yield: 1.07 
g, 85.8%). 
The degree of derivatization with β-Glutamic acid was determined by 1H-NMR. 
The signals of β-Glutamic acid are m, 4.50 ppm -NHCH(CH2)2-, m, 2.59 ppm -
NHCH(CH2)2(COOH)2 and m, 2.44 ppm -NHCH(CH2)2CONH-). The molecular 
weight of Boc-NH-PEG-(β-Glu)-(β-Glu)2-(β-Glu)4-(COOH)8 was calculated by 
MALDI-TOF mass spectrometry. 
 
 
3.3.7 Removal of protecting group t-Boc from Boc-NH-PEG-(β-Glu)-(β-
Glu)2-(β-Glu)4-(COOH)8 
 
1.07 g of Boc-NH-PEG-(β-Glu)-(β-Glu)2-(β-Glu)4-(COOH)8 were dissolved in 4 
ml of CH2Cl2/CF3COOH/H2O (54:45:1 percent) mixture for 1 h to remove the 
protecting group t-Boc (Figure 3.7). The reaction mixture was evaporated to remove 
the TFA and the obtained oil was solubilized in CH2Cl2 and dropped into 300 mL of 
diethyl ether. The product was recovered by filtration and dried under vacuum (yield: 
1.04 g, 97%). 
 
 
 
Figure 3.7: Synthesis of NH2-PEG-(β-Glu)-(β-Glu)2-(β-Glu)4 (COOH)8 
 
The absence of the protecting group t-Boc was confirmed by MALDI-TOF mass 
spectrometry. 
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3.4 SYNTHESIS AND CHARACTERIZATION OF G-CSF-PEG 
CONJUGATES 
 
 
3.4.1 Site-specific conjugation of multicarboxylic and neutral PEGs to G-
CSF 
 
G-CSF-PEG conjugates were obtained by enzymatic PEGylation, exploiting the 
enzyme microbial transglutaminase (mTGase). TGase(s) are a class of enzymes that 
catalyze an acyl transfer between two proteins involving the glutamyl group of a 
glutamine (acyl donor) and a primary amine (acyl acceptor), usually the ε-amino 
group of a lysine. 
mTGase was employed for site-specific binding of PEG to G-CSF, where one of 
its glutamine (Gln) residue serves as acyl donor and an amino-derivative of PEG 
serves as acyl acceptor (Figure 3.8). 
 
 
Figure 3.8: Scheme of G-CSF-PEG synthesis. 
 
For the conjugation of G-CSF, two different multicarboxylic PEGs, PEG-dendron 
and H2N-PEG3.4k-b-PLE50, and two neutral PEG-NH2 derivatives of different 
molecular weight, were used. 
 
3.4.1.1 Removal of protecting group t-Boc from Boc-PEG3.4k-b-PLE50 
 
The Boc group of the polymer Boc-NH-PEG3.4k-b-PLE50 was removed to obtain a 
free amine at one end of the polymer needed for the conjugation reaction (Figure 
3.9). 
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Figure 3.9: Structural formula of Boc-NH-PEG3.4k-b-PLE50. 
 
73 mg of Boc-PEG3.4k-b-PLE50 were dissolved in 4 ml of CH2Cl2/CF3COOH/H2O 
(54:45:1 percent) mixture and were stirred for 1 h. The reaction mixture was 
evaporated to remove the TFA and the obtained oil was solubilized in Milli-Q water. 
The solution was neutralized and dialyzed overnight against Milli-Q water. The 
polymer solution was then lyophilized (yield: 69 mg, 94.5%). 
The absence of the protecting group t-Boc was confirmed by MALDI-TOF mass 
spectrometry. 
 
 
3.4.1.2 Synthesis and purification of G-CSF-PEG conjugates via mTGase-
mediated PEGylation 
 
Generally, to 975 μl (0.21 µmol, MW 18792.8 Da) of a G-CSF solution in 50 mM 
phosphate and 5% sorbitol, pH 7, a defined amount of PEG, previously dissolved in 
the reaction buffer (100 mM phosphate, pH 7.5), was added. The contents used for 
each PEG were shown in Table 3.2 based on the molar excess with respect the 
protein. 
mTGase was added to the solution at an enzyme to substrate ratio (E/S) of 1:25 
(w/w) in order to reach a 0.1 mM final concentration in protein. The reactions were 
incubated at 25°C for 4 hours and then analyzed by RP-HPLC using a Phenomenex 
Jupiter C18 column (250 × 4.6 mm) with a linear gradient of 40–70% (v/v) 
acetonitrile containing 0.01% TFA over 25 min, followed by an isocratic wash at 
90% acetonitrile. The effluent was monitored by measuring the absorbance at 226 
nm. 
 
Table 3.2: Polymer contents used for the synthesis of G-CSF-PEG conjugates. 
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PROTEIN/POLYMER 
RATIO 
MW 
(Da) 
AMOUNT OF PEG 
(mg) 
H2N-PEG5k-(COOH)7 1/50 5717 60.8 
H2N-PEG3.4k-b-PLE50 1/10 11000 23.4 
mPEG5k-NH2 1/10 5000 10.6 
mPEG20k-NH2 1/10 20000 42.6 
 
The conjugates were purified by RP-HPLC using the conditions mentioned above 
and measuring the absorbance of the effluent at 280 nm. After the purification, the 
conjugates were dialyzed against 50 mM phosphate, 5% sorbitol, pH 7 and the 
protein concentrations were determined by UV-Vis spectrophotometry (G-CSF 
absorption coefficients: 0.82 mL cm
−1
). 
The purified conjugates were characterized by MALDI-TOF mass spectrometry, 
SDS-PAGE, and circular dichroism; and their stability studies were performed via 
circular dichroism, monitoring the unfolding as a function of temperature. The 
conjugates were aliquoted and stored in freezer for the ulterior pharmacokinetic 
studies in rats. 
 
 
3.4.2 MALDI-TOF mass spectrometry 
 
Mass analyses of G-CSF and its PEGylated derivatives were carried out by 
MALDI-TOF mass spectrometry. MALDI, matrix-assisted laser 
desorption/ionization, generates gas phase-ions from protein molecules, which are hit 
by a laser. The MALDI matrix absorbs photon energy from the laser beam and 
transfers it into the excitation energy of the solid system. MALDI matrices are low 
molecular weight organic compounds with low vapour pressure and volatile nature, 
mostly acidic in nature. 
MALDI-MS spectra were performed on a REFLEX time-of-flight instrument 
equipped with a SCOUT ion source operating in positive linear mode. Ions generated 
by a pulsed UV laser beam (nitrogen laser, lambda 337 nm) were accelerated to 25 
kV. A saturated solution of sinapinic acid in acetonitrile/water (1:1, v/v) was used as 
matrix and mixed with the samples dissolved in 0.1% TFA aqueous solution at a v/v 
ratio of 1:1. 
 
 
3.4.3 SDS-PAGE 
 
The purified conjugates G-CSF-PEG5k-(COOH)7, G-CSF-PEG3.4k-b-PLE50, G-
CSF-PEG5k, and G-CSF-PEG20k were analyzed by SDS-PAGE, along with native G-
CSF, to confirm the formation of the desired monoconjugates, and their purity. 
For the analysis, 4 – 15% mini precast gels were used. Each well was fill with 10 
µL of a solution containing 5 µg of protein, previously added of loading buffer 
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(containing glycerol as thickener, SDS as anionic detergent, DTT as reducer and 
bromophenol blue as tracer). Separations were run in 0.025M Tris, 0.192M glycine, 
0.1% SDS at pH 8.3, applying 130 V for 1h. The gel was firstly stained with iodine 
(I2) in the presence of BaCl2 in acidic environment, to color PEG and subsequently 
with Coomassie blue that detect the protein bands.  
 
 
3.4.4 Circular Dichroism 
 
Circular dichroism was used to assess the effect of PEGylation on secondary 
structure of the protein. By comparing the far-UV CD spectra of the native protein 
and its PEGylated derivatives, it is possible to understand if PEGylation caused any 
changes in the secondary structure of the protein. In this study, native G-CSF and the 
G-CSF-PEG conjugates were analyzed by CD in the far-UV region. Moreover, in 
order to evaluate if changes were also due to the purification conditions, a native G-
CSF sample was purified in the same conditions as the conjugates and analyzed as 
well. 
CD spectra were measured on a Jasco J-700 spectropolarimeter equipped with a 
Peltier temperature control unit at 20 °C. Measurements of the samples were made in 
50 mM phosphate, 5% sorbitol, pH 7 buffer at the concentration solutions of 0.1 
mg/mL as spectrophotometrically determined at 280 nm. The spectra were collected 
over the wavelength range of 190–250 nm with an average of 2 scans. The data at 
each wavelength were averaged for 8 s. The sample cell path length was 0.1 cm. The 
CD data were converted to mean residue ellipticity, expressed in deg cm
2
 dmol
−1
 by 
applying the following formula: 
 
Θ = Θobs(MRW) / 10 L[C] 
 
where Θ is the observed ellipticity in degrees, MRW is the mean residue weight of 
the protein (molecular weight divided by the number of residues), [C] is the protein 
concentration in mg/mL, and L is the optical path length in centimeters. 
 
 
3.4.5 Thermal denaturation studies 
 
Thermal stability of free and conjugated G-CSF was evaluated by circular 
dichroism, by monitoring the protein unfolding as a function of temperature at a 
fixed wavelength, in order to determine the impact of PEGylation on protein 
stability. Thermal denaturation was monitored on the same samples used for CD 
analysis by recording the decrease of the ellipticity signal at 222 nm. Thermal 
unfolding experiments were carried out in a 0.1 cm cell path length by heating the 
samples from 20 to 95°C at a rate of 5°C/min.  
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3.4.6 In vivo studies 
 
3.4.6.1  Ethics statement 
 
The study protocol was approved by the Ethics Committee of the University of 
Padova and the Italian Ministry of Health, and animals were handled in compliance 
with national (Italian) Legislative Decree 116/92 guidelines and with the “Guide for 
the Care and Use of Laboratory Animals” by the National Research Council of the 
National Academies. 
 
 
3.4.6.2  Pharmacokinetics in rats 
 
The pharmacokinetics of G-CSF and the conjugates were assessed in Sprague-
Dawley rats (250-350 g). The rats were randomly divided into five groups, each 
group containing 3 rats. A dose of 100 μg/kg G-CSF (equiv) was administered via 
tail vein to the rats anesthetized with isoflurane gas (mixed with O2 in enclosed 
cages). Blood samples were collected from the submandibular cheek bleed of the rats 
at pre-determined time points, centrifuged at 1500 × g for 15 min and the serum 
phases were separated. The G-CSF content in serum samples was quantified by 
human G-CSF ELISA kit (Invitrogen). The pharmacokinetic data were elaborated 
using PkSolver, applying a bicompartmental model. 
 
 
3.4.6.3  ELISA 
 
The enzyme-linked immunosorbent assay (ELISA) is a specific and highly 
sensitive method for quantification of proteins in solution. Sandwich ELISA assays 
are so-called because of the layered complex they form. The wells of the plate 
provided are coated with a monoclonal antibody (capture antibody) specific for the 
protein of interest, in this case, human G-CSF. 
Samples, including standards of known protein content and unknowns, were 
pipetted into the wells. A biotinylated monoclonal second antibody (detection 
antibody) was then added and the samples were incubated. During this first 
incubation, the protein was bound simultaneously to the immobilized (capture) 
antibody on one epitope, and to the solution phase biotinylated antibody on a second 
epitope. After removal of excess second antibody, Streptavidin-Peroxidase (enzyme) 
was added, which was bound to the biotinylated antibody to complete the four-
member sandwich. After a second incubation and washing to remove all the unbound 
enzyme, a substrate solution (in this case, tetramethylbenzidine) was added. A color 
reaction was developed between the enzyme and the substrate. The intensity of the 
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colored product was directly proportional to the concentration of the protein present 
in the original sample. The absorbance was read at 450 nm and the protein 
concentration of the analyzed samples was determined by comparison with a 
standard curve of known protein concentrations. 
 
 
Chapter 3 
 
 56 
3.5 SYNTHESIS AND CHARACTERIZATION OF hGH 
CONJUGATES 
 
 
3.5.1 Site-specific conjugation of PEG20kDa to hGH 
 
PEG-hGH conjugates, were formed by conjugation of hGH to PEG20kDa in two 
different sites. The conjugates were obtained exploiting two different strategies 
according to the procedures previously reported by our lab [55]: transglutaminase 
(TGase) mediated enzymatic PEGylation, using PEG20 kDa−NH2 and N-terminal 
PEGylation, based on the use of PEG20kDa –aldehyde. 
 
 
3.5.1.1 Synthesis and purification of PEG-Gln141-hGH 
 
2 mg (90.4 nmol, MW 22129 Da) of hGH were diluted with 0.1 M phosphate 
buffer (pH 7.0) containing 50% of ethanol (v/v) in order to reach a 0.18 mM final 
concentration in protein. 18 mg (0.9 µmol, MW 20000 Da) of PEG20 kDa−NH2 (10-
fold molar excess) was dissolved in this solution and mTGase was added at E/S ratio 
of 1:20 (w/w). 
The mixture was stirred at room temperature for 18 h and then analyzed and 
purified by RP-HPLC using a Phenomenex Jupiter C18 column (250 × 4.6 mm), 
detection at 280 nm, with a linear gradient of 40–80% (v/v) acetonitrile containing 
0.01% TFA over 25 min, followed by an isocratic wash at 90% acetonitrile. After the 
purification, the solution was concentrated under vacuum and the conjugate was 
dialyzed against PBS solution. The protein concentration was determined by UV-
VIS absorption and the conjugate was characterized by SDS-PAGE, MALDI-TOF 
mass spectrometry and circular dichroism. 
 
 
3.5.1.2 Synthesis and purification of PEG-Nter-hGH 
 
Conjugation with PEG-aldehyde allows modification of primary amines of 
proteins. The reaction was performed in acidic condition to protonate the ε-amines of 
the protein while the α-NH2 group was still partially present as free base and 
available for reaction with aldehydes. Therefore, PEG-aldehyde selectively formed 
Schiff’s base with the α-amino group that was after reduced to a secondary amine by 
sodium cyanoborohydride. The scheme of synthesis is shown in Figure 3.10. 
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Figure 3.10: Scheme of PEG-Nter-hGH synthesis. 
 
2 mg (90.4 nmol, MW 22129 Da) of hGH were diluted with 0.1 M acetate buffer 
(pH 5.0) in order to reach a 0.36 mM final concentration in protein. 9 mg (0.45 µmol, 
MW 20000 Da) of PEG20 kDa−aldehyde (5-fold molar excess) were dissolved in this 
solution and after 1 h NaCNBH3 (50-fold molar excess) was added. 
The mixture was stirred at room temperature for 5 h and then analyzed by SEC-
HPLC using a Zorbax GF-250 column (250 × 4.6 mm) eluted with 0.1M phosphate 
buffer, 0.2 M NaCl (pH 7.2) containing 20% (v/v) of ACN. The effluent was 
monitored by measuring the absorbance at 280 nm. The conjugate was purified by 
RP-HPLC using a Phenomenex Jupiter C18 column (250 × 4.6 mm) with a linear 
gradient of 40–80% (v/v) acetonitrile containing 0.01% TFA over 25 min, followed 
by an isocratic wash at 90% acetonitrile. The effluent was monitored by measuring 
the absorbance at 280 nm. After the purification, the solution was concentrated under 
vacuum and the conjugate was dialyzed against PBS solution. The protein 
concentration was determined by UV-VIS absorption and the conjugate was 
characterized by SDS-PAGE, MALDI-TOF mass spectrometry and CD. 
 
 
3.5.2 Characterization of PEG-hGH conjugates 
 
The conjugates were characterized by MALDI-TOF mass spectrometry, SDS-
PAGE, and circular dichroism as described in sections 3.4.2, 3.4.3 and 3.4.4. 
Thermal denaturation of the free and conjugated hGH was monitored on the same 
samples used for CD analysis by recording the decrease of the ellipticity signal at 
208 nm as a function of the temperature. Thermal unfolding experiments were 
carried out in a 0.1 cm cell path length by heating the samples from 20 to 95°C at a 
rate of 5°C/min. CD spectra in the full far UV range were then collected at 20°C, 
95°C, and at 20°C after heating up to 95°C. 
 
 
3.5.3 Site-specific conjugation of poly(L-glutamic acid) to hGH 
 
Conjugation with poly(L-glutamic acid) is an N-terminal PEGylation via 
aldehyde. The polymer was provided with the aldehyde function protected by an 
acetal group. The mechanism of reaction is explained in section 3.5.1.2. 
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3.5.3.1 Removal of acetal group from PLE50ald 
 
The acetal group of the polymer PLE50ald was removed to obtain the aldehyde at 
one end of the polymer (Figure 3.11). 
 
 
 
Figure 3.11: Hydrolysis of acetal group of PLE50ald. 
 
90 mg (13.2 µmol, MW 6800 Da) of PLE50ald were dissolved in 2 ml of 25 mM 
phosphate buffer, pH 2.15 and were stirred at 60°C. After 3 h the solution was 
normalized and dialyzed overnight against Milli-Q water. The polymer solution was 
then lyophilized (yield: 72 mg, 80%). 
The absence of the protecting group t-Boc was confirmed by MALDI-TOF mass 
spectrometry. 
 
 
3.5.3.2 Selection of the synthesis conditions of hGH-PLE50ald 
 
In order to achieve the proper conditions that led to a selective formation of a 
monoconjugate, several options were tested. Buffer, excess of polymer and 
temperature were chosen as variables and were varied. In particular, the reaction 
buffers were 100 mM phosphate, pH 6.2 and 100 mM acetate, pH 5 and 5, 10 and 20 
equivalents of polymer were used at different temperatures (5, 24, 35, 40 and 45°C). 
Generally, to 500 µg (22.6 nmol, MW 22129 Da) of hGH, a defined amount of 
PLE50ald (MW 6726 Da), previously dissolved in the reaction buffer, was added in 
order to reach a 0.36 mM final concentration in protein. The reactions were 
incubated at the temperatures over mentioned and after 1 h, NaCNBH3 (50-fold 
molar excess) was added. After 18 hours incubation at the proper temperature, the 
products formation was evaluated by SDS-PAGE and the data elaboration was 
performed by ImageJ software in order to calculate the percentage formation of 
monoconjugate and biconjugate. 
 
 
3.5.3.3 Synthesis and purification of hGH-PLE50ald 
 
To 5 mg (0.22 µmol, MW 22129 Da) of hGH, 7.6 mg (1.13 µmol, MW 6726 Da) 
of PLE50ald, previously dissolved in 100 mM phosphate buffer, pH 6.2, were added in 
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order to reach a 0.36 mM final concentration in protein. The reaction was incubated 
at 35°C and after 1 h, NaCNBH3 (50-fold molar excess) was added. After 18 hours 
incubation at 35°C, the reaction mixture was analyzed by SEC-HPLC using a Zorbax 
GF-250 column (250 × 4.6 mm) eluted with 0.1M phosphate buffer, 0.2 M NaCl (pH 
7.2) containing 20% (v/v) of ACN. The effluent was monitored by measuring the 
absorbance at 280 nm. 
The conjugate was purified by RP-HPLC using a Phenomenex Jupiter C18 
column (250 × 4.6 mm) with a linear gradient of 40–80% (v/v) acetonitrile 
containing 0.01% TFA over 25 min, followed by an isocratic wash at 90% 
acetonitrile. The effluent was monitored by measuring the absorbance at 280 nm. 
After the purification, the solution was concentrated under vacuum and the conjugate 
was dialyzed against PBS solution. The protein concentration was determined by 
UV-VIS absorption (hGH absorption coefficients: 0.79 mL cm
−1
) and the conjugate 
was characterized by MALDI-TOF mass spectrometry, SDS-PAGE, and circular 
dichroism as described in sections 3.4.2, 3.4.3 and 3.4.4. 
 
 
3.5.4 Pharmacokinetic studies in rats of hGH-PLE50ald 
 
Pharmacokinetic profiles of free and conjugated hGH were determined in 
Sprague-Dawley rats (250-350 g). The rats were randomly divided into two groups 
of 3 animals per group. A dose of 100 µg/kg hGH (equiv.) was administered via tail 
vein to the rats anesthetized with 5% isoflurane gas (mixed with O2 in enclosed 
cages). At predetermined times blood samples were collected from the tail vein and 
centrifuged at 1500 × g for 15 min. The hGH content in serum samples was 
quantified using the hGH ELISA kit. The pharmacokinetic data elaboration was 
performed by PkSolver program applying a bicompartmental model. 
 
 
3.5.5 Pharmacodynamic Study in Hypophysectomized (HYPOX) Rats 
 
In this study, hGH, hGH-PLE50ald, PEG-Gln141-hGH and PEG-Nter-hGH were 
tested to evaluate and compared the efficacy of the conjugate and the native protein 
on the stimulation of somatic growth in hypophysectomized male Sprague Dawley. 
In hypophysectomized rats the pituitary gland was removed by surgery, therefore 
they can’t produce somatotropin. The considered parameters, indices of somatic 
growth, were the weight gain, the femoral length and the width of the tibial cortical 
bone tissue of diaphysis. 
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3.5.5.1 Weight Gain Test 
 
Hypophysectomized male Sprague Dawley rats were purchased from Charles 
River Laboratories (Lecco, Italy) and weighed about 90 g at study initiation. Rats 
were randomized by weight in five groups (n = 6). The first group received daily, via 
tail vein, vehicle solution (PBS, 200 µL). A 30 μg/rat/day of native hGH was 
administered to the second group for 6 days. The third, the fourth and the fifth 
groups received a single injection (tail vein) at the beginning of the experiment of 
180 µg/rat (hGH equiv.) of, respectively, hGH-PLE50ald, PEG-Gln141-hGH and 
PEG-Nter-hGH. Protein solutions were prepared in vehicle solution. Animals were 
followed for 6 days and body weight measurements were taken at the same time 
every day until the end of the study. 
At day 7, animals were sacrificed and their femurs and tibias harvested for the 
measurements as following specified. The collected femurs and tibias have been 
preserved in 10% neutral buffered formalin until needed. 
 
 
3.5.5.2 Femoral length and width of the tibial cortical bone tissue of 
diaphysis measurements. 
 
Femurs were measured with a vernier caliper to determine the length while tibias 
were fixed in 10% neutral buffered formalin, then decalcified in 5% formic acid for 
96 h paraffin embedded. One µm sections were stained with toluidine blue. The 
width of the cortical bone of the tibial diaphysis was measured on the right tibia (the 
results were the average of at least 20 measurements per tibia). 
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3.6 SYNTHESIS AND CHARACTERIZATION OF PEG-KR14 
CONJUGATE 
 
 
3.6.1 Synthesis of azidoproline 
 
3.6.1.1 Mesylation of Boc-L-proline methyl ester 
 
The hydroxyl group of Boc-L-proline methyl ester was modified with 
methanesulfonyl chloride (CH3SO2Cl) in basic condition as reported in figure 3.12. 
 
 
 
Figure 3.12: Reaction scheme of Boc-L-proline methyl ester mesylation. 
 
5 g (0.02 moles MW 245.27 Da) of Boc-L-proline methyl ester were dissolved in 
ice-cold CH2Cl2 (100 mL) and 5.7 ml (0.041 moles, 2 equivalent, MW = 101.19 Da, 
d=0.726 g/ml) of Et3N were added. 3.2 ml (0.041 moles, 2 equivalent, MW = 114.55 
Da, d=1.48 g/mL) of CH3SO2Cl, previously diluted with 50 ml of CH2Cl2, were then 
added dropwise with funnel under ice condition. 
The reaction was left under stirring and monitored with TLC. After 7 hours, the 
reaction was stopped adding 50 mL of H2O and washed with 1M HCl (50 mL) (to 
remove the excess amount of CH3SO2Cl and Et3N), then with saturated aHCO3 
solution (50 mL) (to remove non-reacted proline, HCl, and Et3N.HCl) and then with 
saturated NaCl solution. The organic layer was dried with anhydrous Na2SO4 and the 
CH2Cl2 was evaporated to obtain a brown oil, left under vacuum overnight (MW 
323.36 Da, yield: 5.87 g, 93.9 %). 
 
 
3.6.1.2 Nucleophilic Substitution of Mesyl by azido group 
 
The mesyl group was converted to an azide, needed for the following Click 
Chemistry to react with the alkyne ethynylferrocene. To this aim, sodium azide, 
which is a nucleophile, was used. The mesyl substituent was an (R) configuration 
and, after the nucleophilic substitution, the azide has changed in (S) (Figure 3.13). 
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Figure 3.13: Nucleophilic substitution of mesyl group. 
 
5.87 g of mesylated Boc-L-proline methyl ester were dissolved in 60 mL DMF 
and 1.75 g (0.027 moles, 1.5 equivalent, MW = 65.01 Da) of NaN3 were slowly 
added. The reaction was stirred overnight under 80°C and then cooled down to room 
temperature. EtOAc (150 ml × 2) was used to extract the azidoproline and the 
organic layer was washed with saturated NaCl solution, dried with anhydrous 
Na2SO4, evaporated to obtain a brown oil and left under vacuum overnight (MW 
270.13 Da, yield: 4.04 g, 85.7 %). 
 
 
3.6.1.3 Deprotection of the Methyl Ester 
 
The azidoproline was dissolved in 80 ml of a mixture THF/NaOH 2N (1:1 v/v), 
left to reflux for 2 hours and stirred overnight. After removing the organic phase 
under reduced pressure, 15 ml of DCM were added to extract the water layer. 
Concentrated HCl was used to acidify the extracted layer and then, EtOAc (20 ml) 
was added and the mixture was stirred overnight. 
EtOAc layer was washed with saturated NaCl solution, dried with anhydrous 
Na2SO4, evaporated to obtain a light brown oil and left under vacuum overnight 
(MW 256.12 Da, yield: 3.17 g, 83.1 %). The scheme of reaction is reported in figure 
3.14. 
 
 
 
Figure 3.14: Hydrolysis reaction for the removing of the methyl. 
 
 
3.6.1.4 Substitution of N-Boc group with Fmoc 
 
The azidoproline was dissolved in 15 ml of DCM, 15 ml of TFA were added 
under ice condition and the reaction was stirred under ice for 30 min and at RT for 2 
hours. The TFA was removed under gentle N2 stream and the residue was dissolved 
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in 15 mL of H2O. Na2CO3 was added to reach pH 9 and then 8.3 g (0.024 moles, 2 
equivalent, MW = 337.3 Da) of Fmoc-Osu were added, previously solubilized in 10 
ml of THF. The reaction was stirred overnight. 
The water layer was extracted with ether and normalized with concentrated HCl 
under ice condition to achieve the formation of a white solid that was finally 
recovered with EtOAc extractions (20 ml × 2). The organic layer was washed with 
saturated NaCl solution, dried with anhydrous Na2SO4, evaporated to obtain a 
white/pink solid that was left under vacuum overnight (MW 378.38 Da, yield: 3.33 
g, 79.5 %). The scheme of reaction is reported in figure 3.15. 
 
 
 
Figure 3.15: Deprotection of the N-Boc group and protection of NH group with Fmoc. 
 
 
3.6.2 Synthesis of KR14 using CEM microwave synthesizer 
 
The peptide triazole KR14 (Figure 3.16) was synthesized by CEM microwave 
synthesis using Fmoc chemistry on a Rink amide resin at a 0.25 mM scale. 
 
 
 
 
 
 
 
Figure 3.16: KR14 structure. 
 
The amino acid solutions were prepared at a concentration of 0.3 M in DMF and 
for the 0.25 mM scale, 0.446 g of resin were used. The deprotector, the activators 
and the main wash solvent were a solution of piperidine 20% in DMF, DCI/HOBT 
(N,N'-Diisopropylcarbodimide/1-Hydroxybenzotriazole) and DMF respectively. 
After the assembling of the residues, the resin was diluted in 15 ml of THF and 
0.5 g of Boc-anhydride were added for the N-terminal protection. The reaction was 
stirred for 7 hours at RT and then the resin was filtered and washed with DCM. 
After drying, a [3+2] cycloaddition reaction was completed using 
ethynylferrocene. For the click reaction, a mixture of 4.24 ml of acetonitrile, 4.24 ml 
of H2O, 1.06 ml of DIPEA and 0.53 ml of pyridine was prepared, 20 mg of CuI and 
300 mg of ethynyl ferrocene were added and the reaction was stirred at room 
H
H
H
H
H
H
H
H
Fe
NH
2
SH
O
N
N
N
N
N
NH
NH
2
NH
NH
2
N
N
N
O
O
NH
2
O
O
NH
2
O
O
N
O
N
N
N
N
H
N
H
O
O
OH
O
HOOC
O
O
N
H
N
H
N
H
N
H
S
O
S
O
O
O
NH
2
O
N
H
O
Chapter 3 
 
 64 
temperature overnight. Subsequently, the resin was filtered and taken in to cleavage 
cocktail of 95:2:2:1 trifluoroacetic acid (TFA)/1, 2-ethanedithiol/water/thioanisole 
for 2 h. Separated the resin, the solution was precipitated in cold diethyl ether. The 
crude peptide was recovered for centrifugation and was dissolved in 50% ACN/H2O 
and purified by RP HPLC (Beckmann Coulter) on a preparative C18 column (100 Å, 
2.14 × 25 cm) with a linear gradient of 5–95 % of ACN/water in 0.1% TFA. The 
final purified peptide were lyophilized and validated by MALDI-TOF mass 
spectrometry. 
 
 
3.6.3 Conjugation of PEG-Maleimide to KR14 
 
 
Figure 3.17: The thiol group of KR14 is conjugated to maleimide of PEG. 
 
To 4 mL (0.94 mmol, MW 2126 Da) of a KR14 solution (0.5 mg/mL) in DMSO, 
42.7 mg ( 2.13 mmol, 2-fold molar excess, MW 20000 Da) of PEG20kDa–Mal were 
added and the mixture was left to stir at room temperature for 18 h (Figure 3.17). The 
conjugation reaction was monitored by SEC-HPLC using a Phenomenex BioSep-
SEC-S 4000 column (7.8 × 300 mm) eluted with 0.1 M phosphate buffer, pH 6.8, 
containing 20% (v/v) of acetonitrile. The effluent was monitored by measuring the 
absorbance at 280 nm. Then, 3 equivalents of thioglycolic acid (TGA), with respect 
to each equivalent of PEG20kDa–Mal, were added to the reaction mixture to block the 
reactive maleimide group. The conjugates were dialyzed against PBS (phosphate 
buffered saline), pH 7.2, using a membrane with cut-off of 14000 MWCO. The 
peptide concentrations were determined by UV absorption at 280 nm (absorption 
coefficients: 2.86 mL cm
-1
 mg
-1
) and the characterization was carried out by SEC-
HPLC and MALDI-TOF mass spectrometry. 
 
 
3.6.4 Pharmacokinetic studies of KR14 and PEG-KR14 
 
The pharmacokinetic profiles of PEG-KR14 and free KR14 were evaluated in rats 
by labeling the peptide moiety with fluorescein. 
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3.6.4.1 Preparation of 5-FM-KR14 
 
KR14 was labeled with fluorescein exploiting the free thiol group (Figure 3.18). 
The binding of 5-FM to the free cysteine of the peptides prevented the formation of 
PT dimers in vivo. 
 
 
 
Figure 3.18: The thiol group of KR14 is conjugated to maleimide of fluorescein. 
 
The reaction was performed at a peptide concentration of 1 mg/mL in DMSO and 
an excess of 0.8 eq of fluorescein-5-maleimide (5-FM). TGA was added using an 
excess of 1.5 eq compared to fluorescein. The reaction was monitored and purified 
by RP-HPLC. The product was characterized by ESI-TOF analyses and the loading 
of fluorescein was determined by UV-VIS absorption (absorption coefficients: 2.86 
mL cm
-1
 mg
-1
). 
 
 
3.6.4.2 Preparation of FITC-PEG-KR14 
 
PEG-KR14 was labeled with fluorescein through the N-terminal amino group of 
the peptide (Figure 3.19). 
 
 
 
Figure 3.19: Free amino group of peptide is conjugated to isothiocyanate group of fluorescein. 
 
The reaction was carried out at a PEG-KR concentration of 1 mg/mL in DMSO, 
an excess of 5 eq (0.94 mmol, MW 2126 Da) of fluorescein isothiocyanate (FITC) 
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and 1 eq TEA. The products were purified by dialysis and analyzed by SEC. The 
loading of fluorescein was determined by UV-VIS absorption using the extinction 
coefficient of FITC (absorption coefficients: 2.86 mL cm
-1
 mg
-1
). 
 
 
3.6.4.3 Pharmacokinetics 
 
Pharmacokinetic profiles of free and conjugated peptide were determined in 
Balb/c mice. 5-MF-KR14 and FITC-PEG-KR14 were solubilized in saline buffer and 
were administered via tail vein to rats anaesthetized with isoflurane gas (mixed with 
O2 in enclosed cages). At predetermined times, blood samples were withdrawn, 
centrifuged, PBS (Phosphate Buffer Saline) were added and then the fluorescence 
was determined.  
 
 
3.6.5 Surface Plasmon Resonance competition experiments 
 
Surface plasmon resonance (SPR) technique is an optical method for measuring 
the refractive index of very thin layers of material adsorbed on a metal. The SPR 
technique is based on the fact that, at certain conditions, surface plasmons on a 
metallic film can be excited by photons, thereby transforming a photon into a surface 
plasmon and it depend on the refractive index of the adsorbate. In the Biacore system 
the principal determinant at which the angle of incidence occurs is the refractive 
index close to the backside of the metal film, to which target molecules are 
immobilized and addressed by ligands in a mobile phase running along a flow cell. If 
binding occurs to the immobilized target, the local refractive index changes, leading 
to a change in SPR angle, which is monitored in real time by detecting changes in the 
intensity of the reflected light, producing a sensorgram (Figure 3.20). 
 
 
Figure 3.20: Typical set-up for an SPR biosensor. 
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All surface plasmon resonance (SPR) experiments were performed on a Biacore 
3000 optical biosensor. A CM5 sensor chip was derivatized by amine coupling by 
using N-ethyl-N-(3-dimethylaminopropyl)carbodiimide/N-hydroxy-succinimide 
(Ishino et al., 2006) with soluble CD4, mAb 17b Fab, or as a control surface 
mAb2B6R (antibody to human IL-5 receptor a). For competition experiments,ligands 
(sCD4 and 17b mAb,) were immobilized on a surface with a density of 
approximately 2000 RU. Fixed solutions of gp120 were passed over the surfaces at a 
flow rate of 50 mL/min with 2.5 min association phase and 2.5 min dissociation 
phase, mixed to different amounts of native or modified peptide. Surfaces were 
regenerated by using 35mM NaOH and 1.3M NaCl for sCD4 and 10mM HCl for 17b 
surface. Data analysis was performed using BIAEvaluation1 4.0 software. The 
responses of a buffer injection and responses from the control surface to which the 
mAb 2B6R was immobilized, were subtracted to account for nonspecific binding. 
The inhibitor concentration at 50% of the maximal response (IC50) was calculated. 
The inhibition curve was converted into a calibration curve by the use of a fitting 
function. Results were given as the percentage of gp120 bound relative to gp120 
bound in the absence of peptide: 100×[(RU−RUgp120)/RUgp120]. 
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4.1 SYNTHESIS OF NH2-PEG-(β-Glu)-(β-Glu)2-(β-Glu)4-(COOH)8 
 
NH2-PEG-(β-Glu)-(β-Glu)2-(β-Glu)4-(COOH)8, also termed PEG-dendron, is a 
multicarboxylic polymer characterized by the presence of carboxylic groups 
(─COOH) which confer the polyanionic characteristic to the polymeric chain. PEG-
dendron was synthetized starting from Boc-NH-PEG5k-NHS (MW 5003 Da) and it 
was derivatized at the NHS end with a symmetric bicarboxylic unit, namely β-
glutamic acid, which provides a branched structure that doubles the number of 
negative charges at each generation. The other end of the heterobifunctional chain 
offers an amino group suitable for enzymatic PEGylation via tranglutaminase (Figure 
4.1) 
 
Figure 4.1: PEG-dendron. 
 
The reaction steps have provided the formation of an amide bond between the 
activated carboxyl group of PEG and the amino group of β-glutamic acid, alternated 
to the consequently activation of the new carboxylic groups. The last step was the 
removal of the protecting group t-Boc to obtain the free amino group. 
The results of the synthesis were reported in table 4.1. 
 
Table 4.1: Results of the synthesis of PEG-dendron. 
 
Synthesis step 
Yield 
(%) 
Activation 
degree (%) 
Synthesis of Boc-NH-PEG-β-Glu-(COOH)2 87  
Activation of Boc-NH-PEG-β-Glu-(COOH)2  81.6 
Synthesis of Boc-NH-PEG-(β-Glu)-(β-Glu)2-(COOH)4 78.4  
Activation of Boc-NH-PEG-(β-Glu)-(β-Glu)2-(COOH)4  83.5 
Synthesis of Boc-NH-PEG-(β-Glu)-(β-Glu)2-(β-Glu)4- (COOH)8 85.8  
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4.1.1 Characterization of Boc-NH-PEG-(β-Glu)-(β-Glu)2-(β-Glu)4-
(COOH)8 
 
The degree of derivatization with β-Glutamic acid was determined by 1H-NMR. 
In figure 4.2 PEG-dendron 
1
H-NMR spectrum was compared to Boc-NH-PEG5k-
NHS one. The signals of β-Glutamic acid are m, 4.50 ppm -NHCH(CH2)2-, m, 2.59 
ppm -NHCH(CH2)2(COOH)2 and m, 2.44 ppm -NHCH(CH2)2CONH-). 
 
 
Figure 4.2: 
1
H-NMR spectroscopy of Boc-NH-PEG5k-NHS (green spectrum) and PEG-
dendron (black spectrum). 
 
After the integration of the signals (Table 4.2), 6 units of β-Glu were found to 
form the PEG-dendron, which reflect the presence of 7 carboxylic groups instead the 
8 expected. 
 
Table 4.2: Integration of the signals. 
 
δ 
(ppm) 
Multiplicity 
Theoric 
integration 
Sperimental 
integration 
Attribution 
4.5 m 7 3.87 -NHCH(CH2)2- 
2.59 m 16 25.48 -NHCH(CH2)2(COOH)2 
2.44 m 12  -NHCH(CH2)2CONH- 
1.43 s 9 9 -OC(CH3)3 
 
 
4.1.2 Removal of protecting group t-Boc from Boc-PEG5k-(COOH)7 
 
The deprotection of the amino group was performed in acidic condition where the 
Boc group dissociates. The absence of the protecting group was confirmed by 
MALDI-TOF mass spectrometry. As reported in figure 4.3, the signal at δ = 1.43 
ppm (multiplicity s) was absent. 
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Figure 4.3: 
1
H-NMR spectroscopy of PEG5k-(COOH)7. 
 
The molecular weight of Boc-NH-PEG-(β-Glu)-(β-Glu)2-(β-Glu)4-(COOH)7 was 
calculated by MALDI-TOF mass spectrometry and was found to be 5717 Da that 
corresponds to the derivatization with 6 units of β-Glu (Figure 4.4). 
 
 
 
 
 
 
 
 
 
Figure 4.4: MALDI-TOF spectra of PEG5k-(COOH)7. 
Mass (m/z)
3000 4000 5000 6000 7000 8000
R
e
la
ti
v
e
 i
n
te
n
s
it
y
5717 Da 
Chapter 4 
 
 74 
4.2 SYNTHESIS AND CHARACTERIZATION OF G-CSF-PEG 
CONJUGATES 
 
 
4.2.1 Removal of protecting group t-Boc from Boc-PEG3.4k-b-PLE50 
 
The absence of the protecting group was confirmed by MALDI-TOF mass 
spectrometry. As reported in figure 4.5, the signal at δ = 1.43 ppm (multiplicity s) 
was absent. 
 
 
 
Figure 4.5: 
1
H-NMR spectroscopy of Boc-NH-PEG3.4k-b-PLE50 (green spectrum) and Boc-
NH-PEG3.4k-b-PLE50 (black spectrum). 
 
 
4.2.2 Site-specific conjugation of multicarboxylic and neutral PEGs to G-
CSF 
 
G-CSF-PEG conjugates were obtained by enzymatic PEGylation, exploiting the 
enzyme microbial transglutaminase (mTGase). mTGase-mediated conjugations were 
achieved as described in section 3.4.1.2 and have allowed the site-specific binding of 
PEG to G-CSF, where only one of its 17 glutamines (Gln135) was the substrate for 
the enzyme. 
The conjugates were analysed, purified and characterized by: i) RP-HPLC to 
remove the free rhG-CSF, ii) MALDI-TOF mass spectrometry to confirm the 
formation of the products, iii) SDS-PAGE to validate the purity, iv) circular 
dichroism to assess the effect of PEGylation on secondary structure of the protein. 
 
 
4.2.2.1 HPLC profiles 
 
The reactions were monitored by RP-HPLC at t = 0’ (before the addition of 
mTGase) and after 4 hours of incubation of G-CSF with the polymer in the presence 
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of mTGase. In figure 4.6 the chromatography profiles of G-CSF-PEG conjugates are 
shown. 
The conjugates retention time (tr about 21 min) were different from free G-CSF (tr 
= 23 min). The yield of the reactions, calculated from the peak areas, were 74.3, 
61,86 and 70% for G-CSF-PEG5k-(COOH)7, G-CSF-PEG3.4k-b-PLE50, G-CSF-PEG5k and 
G-CSF-PEG20k respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Scheme of rhG-CSF-PEG synthesis. 
 
Figure 4.6: Chromatography profiles of G-CSF-PEG5k-(COOH)7 (A), G-CSF-PEG3.4k-b-
PLE50 (B), G-CSF-PEG5k (C) and G-CSF-PEG20k (D) mixture reactions. 
 
 
4.2.2.2 MALDI-TOF spectra 
 
The molecular weights of the conjugates were determined by MALDI-TOF mass 
spectrometry and they correspond to one molecule of G-CSF (18792.8 Da) bound to 
one chain of H2N-PEG5k-(COOH)7 (5717 Da), H2N-PEG3.4k-b-PLE50 (11000 Da), 
mPEG5k-NH2 (5000 Da) or mPEG20k-NH2 (20000 Da) respectively (Figure 4.7). 
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Figure 4.7: MALDI-TOF spectra of G-CSF-PEG5k-(COOH)7 (A), G-CSF-PEG3.4k-b-PLE50 
(B), G-CSF-PEG5k (C) and G-CSF-PEG20k (D). 
 
 
4.2.2.3 SDS-PAGE 
 
The purified conjugates G-CSF-PEG5k-(COOH)7, G-CSF-PEG3.4k-b-PLE50, G-
CSF-PEG5k, and G-CSF-PEG20k were analyzed by SDS-PAGE (figure 4.8), along 
with native G-CSF, to confirm that the synthesis reactions resulted in the formation 
of the desired monoconjugates, and to demonstrate that the purification of the 
conjugates were achieved successfully. 
 
 
Figure 4.8: Gel electrophoresis of G-CSF (1), G-CSF-PEG20k (2), G-CSF-PEG3.4k-b-PLE50 
(3), G-CSF-PEG5k (4), G-CSF-PEG5k-(COOH)7 (5), and marker (6). A) Colored with iodine. B) 
Colored with Coomassie blue. 
 
The presence of the bands in both iodine and Coomassie blue coloration confirms 
that G-CSF was PEGylated in all four reactions. Molecular weights of the PEGylated 
conjugates on the gel are higher than their real values because PEG has a greater 
hydrodynamic volume than a protein of the same molecular weight. Moreover, the 
purified PEGylated derivatives of G-SCF are monoconjugates and pure. 
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4.2.2.4 Circular Dichroism 
 
The investigation of the secondary structure of G-CSF and its PEGylated 
derivatives was carried out by far-UV circular dichroism in order to study the effect 
of the polymer on the protein surface. By comparing the far-UV CD spectra of a 
native protein and its PEGylated derivatives, it is possible to understand whether or 
not PEGylation caused any changes in the secondary structure of the protein. 
The CD scans were carried out in 50 mM phosphate, 5% sorbitol, pH 7 buffer 
where the protein is more stable. The spectra showed that the G-CSF still maintained 
its secondary structure after conjugation as the profiles of native G-CSF and 
PEGylated forms were quite similar, thus suggesting that the polymer chain did not 
modify the protein conformation (figure 4.9). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: CD spectra of G-CSF and its PEGylated derivatives. 
 
 
4.2.3 Stability studies 
 
Circular dichroism can also be used to determine the thermal stability of proteins 
and the impact of PEGylation on protein stability, by monitoring the protein 
unfolding as a function of temperature at a fixed wavelength. G-CSF has 4 α-helices. 
Proteins with high α-helical content present peaks at 190-195 nm, 208 nm, and 222 
nm and their unfolding studies are usually performed at 222 nm because α-helical 
proteins have a strong ellipticity signal at that wavelength, whereas unfolded proteins 
have no or little signal. In this CD analysis, temperature was progressively increased 
from 20°C to 90°C, with a temperature slope of 2°C/min. 
Melting profiles of the G-CSF-PEG conjugates (Figure 4.10) showed that 
conjugates were slightly less stable than the native G-CSF. However, the purified G-
CSF had almost the same melting profile as the conjugates, suggesting that the 
decrease in the stability of the protein after PEGylation is probably due to the 
purification conditions. Melting temperatures (the temperature where the unfolded 
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fraction is 50%) of the native G-CSF and its PEGylated derivatives were determined 
and reported in table 4.3. 
 
 
 
 
 
 
 
 
4.2.4 SDS-PAGE 
 
 
Figure 4.10: Temperature dependence of the CD intensity at 222 nm. 
 
Table 4.3: Melting temperatures of G-CSF and its PEGylated derivatives. 
 
Compound Tm (°C) 
Native G-CSF 60 
Purified G-CSF 56.6 
G-CSF-PEG5k-(COOH)7 57.4 
G-CSF-PEG3.4k-b-PLE50 57 
G-CSF-PEG5k 56.6 
G-CSF-PEG20k 54 
 
 
4.2.4 Pharmacokinetic studies 
 
The pharmacokinetics of G-CSF and conjugates were assessed in Sprague-
Dawley rats (250-350 g). The rats were randomly divided into five groups, each 
group containing 3 rats and a dose of 100 μg/kg G-CSF (equiv) was administered via 
tail vein. The G-CSF content in serum samples was quantified by human G-CSF 
ELISA kit (Invitrogen). The pharmacokinetic data were elaborated using PKSolver, 
applying a bicompartmental model. 
As shown in figure 4.11, high plasma levels of G-CSF were recorded immediately 
for the native G-CSF and its PEGylated derivatives. The G-CSF level for the native 
protein fell below the detection limit after 7 hours, whereas the conjugates showed 
prolonged half-lives with detectable levels of G-CSF even after 24 hours. 
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Figure 4.11: Pharmacokinetic profiles of G-CSF and its PEGylated derivatives in Sprague-
Dawley rats (n=3). Data are presented as mean ±SD. 
 
All conjugates showed an increase in elimination half-life with respect to G-CSF. 
The half-lives of the conjugates G-CSF-PEG5k-(COOH)7 and G-CSF-PEG3.4k-b-
PLE50, which were coupled to multicarboxylic PEGs of 5717 Da and 11000 Da  
respectively, were comparable with the half-life of the conjugate G-CSF-PEG20k, 
which was coupled to a neutral PEG of 20 kDa. The clearance and the apparent 
volume of distribution of the conjugates were significantly reduced with respect 
those of G-CSF. The key pharmacokinetic parameters are reported in table 4.4. 
 
Table 4.4: Main pharmacokinetic parameters of G-CSF and its PEGylated derivatives after 
i.v. administration of 100 μg/kg G-CSF (equiv) to Sprague-Dawley rats. 
 
Compounds t1/2 α (h) t1/2 β (h) AUC(0→∞) (μg min/mL) Cl (mL/h) VD (mL) 
G-CSF 2.99 2.99 7.56 13.23 57.00 
G-CSF-PEG5k-(COOH)7 1.00 9.80 11.54 8.14 33.72 
G-CSF-PEG3.4k-b-PLE50 1.53 11.31 10.76 8.64 37.83 
G-CSF-PEG5k 1.48 7.72 11.60 8.15 40.81 
G-CSF-PEG20k 0.14 9.97 48.44 8.26 3.63 
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4.3 SYNTHESIS AND CHARACTERIZATION OF hGH 
CONJUGATES 
 
 
4.3.1 Synthesis and characterization of PEG-Gln141-hGH and PEG-
Nter-hGH 
 
Two different site-specific mono-PEGylated forms of human growth hormone 
(hGH) were prepared exploiting an enzymatic PEGylation (PEG-Gln141-hGH) via 
transglutaminase (TGase) and a chemical N-terminal PEGylation (PEG-Nter-hGH). 
The preparation of the conjugates was accomplished as described in section 3.5.1, 
using 20kDa and neutral PEGs. The enzymatic PEGylation was performed in 0.1 M 
phosphate buffer pH 7.0 containing 50% of EtOH (v/v) in order to increase the 
selectivity of mTGase, according to achievements previously reported by our 
research group [Mero 2011]. The chemical PEGylation was conducted in 0.1 M 
acetate buffer pH 5 to direct the modification at the N-terminal, thanks to the lower 
pKa value of the α-amino group with respect to the ε-amino groups. 
The conjugates were analysed and characterized by: i) RP and SEC-HPLC, ii) 
MALDI-TOF mass spectrometry to confirm the formation of the products, iii) SDS-
PAGE to validate the purity, iv) circular dichroism to assess the effect of PEGylation 
on secondary structure of the protein. 
 
 
4.3.1.1 HPLC profiles 
 
The reactions were monitored by RP and SEC after 18 and 5 hours of incubation 
for enzymatic and chemical reaction respectively. In figure 4.12 the chromatography 
profiles of mixtures reaction are shown. 
The yield of the reactions, calculated from the peak areas, were 45% for PEG-
Gln141-hGH and 60% for PEG-Nter-hGH. 
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Figure 4.12: RP and SEC-HPLC analysis of PEG-Gln141-hGH (A) of PEG-Nter-hGH (B) 
mixture reactions. 
 
 
4.3.1.2 MALDI-TOF spectra 
 
The molecular weights of the conjugates, determined by MALDI-TOF mass 
spectrometry, were 44122 Da for PEG-Gln141-hGH and 44153 Da for PEG-Nter-
hGH. The spectra are reported in figure 4.13. 
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Figure 4.13: MALDI-TOF spectra of PEG-Gln141-hGH (A) and PEG-Nter-hGH (B). 
 
 
4.3.1.3 SDS-PAGE 
 
The purified conjugates were analyzed by SDS gel electrophoresis (figure 4.14), 
along with native hGH, to confirm that the synthesis reactions resulted in the 
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formation of the desired monoconjugates, and to demonstrate that the purification of 
the conjugates were achieved successfully. 
 
Figure 4.14: SDS gel electrophoresis of the following: M, Marker; 1, native hGH (22 kDa); 2, 
PEG-Gln141-hGH (~ 66kDa); 3, PEG-Nter-hGH (~ 66kDa). 
 
 
4.3.1.4 Circular Dichroism 
 
Far-UV CD spectra of native protein and PEG-hGH conjugates were compared to 
study the effect of the polymer on the protein surface. 
The CD scans were carried out in PBS buffer and the spectra showed that the 
hGH in both PEG-Nter-hGH and PEG-Gln141-hGH preserved the native secondary 
structure (figure 4.15). 
 
 
 
Figure 4.15: CD spectra of hGH and PEG-hGH conjugates. 
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4.3.2 Thermal stability studies 
 
Thermal denaturation was carried out to investigated if the different PEGylation 
site caused a difference in the thermal stability of the two conjugates. Denaturation 
experiments of hGH and its conjugates were carried out in the temperature range of 
20 – 95°C by measuring the ellipticity at 208 nm (Figure 4.16). The protein 
maintained its secondary structure up to 70 – 75°C and then rapidly lost its native 
structure with a melting temperature of 82°C. Also PEG-Gln141-hGH was found to 
be stable up to about 70 – 75°C and lost its secondary structure with a transition mid-
point at 83.8°C. Otherwise PEG-Nter-hGH displayed a higher thermal stability, with 
a melting temperature of 86.1°C (Table 4.5). 
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Figure 4.16: Temperature dependence of the CD intensity at 208 nm. 
 
Table 4.5: Melting temperatures of hGH, PEG-Gln141-hGH and PEG-Nter-hGH. 
 
Compound Tm (°C) 
hGH 82 ± 1.41 
PEG-Gln141-hGH 83.8 ± 0.57 
PEG-Nter-hGH 86.1 ± 0.42 
 
Reversibility of the thermal unfolding was determined by measuring the recovery 
of the CD signal upon heating (95°C) and cooling (20°C) the hGH and PEGylated 
hGH solutions. As known, native hGH has a predominantly α-helical structure in 
physiological conditions with the two characteristic bands at 222 and 208 nm. 
The CD spectra at 95°C show the disappearance of the bands at 222 and 208 nm, 
which means that the three samples lost their native α-helical structure. The 
conjugates, even at such high temperature, tend to preserve a certain percentage of α-
helical structure with respect to hGH but more remarkably the transition was 
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reversible and partially reversible for PEG-Nter-hGH and PEG-Gln141-hGH, 
respectively, opposing to the permanent denaturation of hGH (Fig. 4.17). 
In the case of PEG-Nter-hGH, after cooling the solutions to 20°C, the CD spectra 
showed a total recovery of the native α-helical structure (Fig. 4.17C). These results 
indicated that PEGylation increased thermal stability of hGH and favored the protein 
refolding, but for a complete recovery the site of PEG conjugation is relevant. 
Moreover PEG-Nter-hGH was found to be more stable than PEG-Gln141-hGH. 
Probably this behavior depends on the way in which the PEG chain is arranged 
around the protein, which in the case of protein N-terminus conjugation, the polymer 
is probably more effective in stabilizing the protein. 
 (nm)
200 210 220 230 240 250
[

(d
e
g
 c
m
2
 d
m
o
l-1
)
-20000
0
20000
40000 20° C
95° C
20° C after melting
(nm)
210 220 230 240 250
[

 d
e
g
 c
m
2
 d
m
o
l-1
)
-20000
-10000
0
10000
20° C
95 ° C
20 ° C after melting
(nm)
200 210 220 230 240 250
[
  
(d
e
g
 c
m
2
 d
m
o
l-1
)
-20000
-15000
-10000
-5000
0
5000
10000
20° C
95° C
20° C after melting
A
B
C
hGH
PEG-Gln141-hGH
PEG-Nter-hGH
 
Figure 4.17: Termal stability of hGH, PEG-Gln141-hGH, and PEG-Nter-hGH by CD 
spectroscopy. CD spectra of hGH, PEG-Gln141-hGH, and PEG-Nter-hGH at 20°C (continuous 
line), 95°C (dashed line), and 20°C after heating up to 95°C (dotted line). 
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4.3.3 Synthesis and characterization of hGH-PLE50ald 
 
hGH has been site-specifically modified at the α-amino group at the protein’s N-
terminus. Conjugation with PLE50ald allows modification of primary amines of 
proteins. hGH contains ten primary amines: the α-amine of Phe1 and the nine ε 
amino groups of Lys residues. In order to achieve the best reaction conditions for the 
obtainment of a monoconjugate, a preliminary study was performed, changing some 
variables. 
 
 
4.3.3.1 Removal of acetal group from PLE50ald 
 
The polymer was provided with the aldehyde function protected by an acetal 
group. After removal of the protecting group as describe in section 3.5.3.1, the 
absence of the protecting group was confirmed by 
1
H-NMR spectroscopy. As 
reported in figure 4.18, the signal at δ = 1.1 ppm (multiplicity t) was absent. 
 
 
 
 
 
 
 
 
 
 
Figure 4.18: 
1
H-NMR spectroscopy of PLE50ald before (A) and after (B) hydrolysis. 
 
 
4.3.3.2 Study of hGH-PLE50ald synthesis conditions 
 
Several reaction conditions were tested to find out the most efficient. Two 
reaction buffers were used (100 mM phosphate, pH 6.2 and 100 mM acetate, pH 5) 
and the polymer molar excess was also varied (5, 10 and 20 equivalents). Finally, the 
reactions were incubated at different temperatures (5, 24, 35, 40 and 45°C) and were 
prepared as described in section 3.5.3.2. 
All the reactions were analysed by SDS-PAGE to evaluate the formation of 
monoconjugate and biconjugate and calculate the corresponding percentages, 
processing the data with ImageJ software. 
The results showed that in phosphate buffer, pH 6.2 the yields of reaction were 
higher than in acetate buffer pH 5, as the protonation of the amines was more 
substantial and then they were less available for the binding to the aldehyde group. 
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Moreover, the increase of the polymer molar excess and also of the temperature led 
to an increase in the biconjugate formation (Figure 4.19). 
The chosen conditions for the synthesis of hGH-PLE50ald have been those that 
allowed the formation of only monoconjugate in the best yield. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19: Selection of the synthesis condition. 
 
The synthesis reaction was performed in 100 mM phosphate buffer, pH 6.2, at 
35°C, using 5 equivalents of polymer as reported in section 3.5.3.3. The conjugate 
was then analysed and characterized by: i) SEC-HPLC, ii) MALDI-TOF mass 
spectrometry iii) SDS-PAGE and iv) circular dichroism. 
 
 
4.3.3.3 HPLC profile 
 
The reaction was monitored by SEC-HPLC after 18 of incubation. In figure 4.20 
the chromatography profiles of mixture reaction is shown. 
The conjugates retention time (tr about 7.8 min) were different from free hGH (tr 
= 9.7 min). The yield of the reactions, calculated from the peak areas, was 75%. 
100mM phosphate, pH 6.2 100 mM acetate, pH 5 
Results 
 
 87 
 
 
 
Figure 4.20: SEC-HPLC analysis of hGH and hGH-PLE50ald. 
 
 
4.3.3.4 MALDI-TOF spectrum 
 
The molecular weight of the conjugate, determined by MALDI-TOF mass 
spectrometry, was 28993 Da. The spectra are reported in figure 4.21. 
 
 
 
 
 
 
 
 
 
Figure 4.21: MALDI-TOF mass spectrum of hGH-PLEald50. 
 
 
4.3.3.5 SDS-PAGE 
 
The purified conjugate were analyzed by SDS gel electrophoresis (figure 4.22), 
along with native hGH, to confirm that the synthesis reactions resulted in the 
formation of the desired monoconjugates, and to demonstrate that the purification of 
the conjugate was achieved successfully. 
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Figure 4.22: SDS gel electrophoresis of the following: M, Marker; 1, native hGH (22 kDa); 2, 
hGH-PLE50ald (29kDa). 
 
 
4.3.3.6 Circular dichroism 
 
The far-UV CD analysis (Figure 4.23), showed that hGH still maintained the 
native secondary structure thus suggesting that conjugation with PLE50ald preserved 
the protein conformation. 
 
 
 
Figure 4.23: Comparison of the secondary structure of native hGH and hGH-PLE50ald by far-
UV CD. 
 
 
4.3.3.7 Pharmacokinetics 
 
Pharmacokinetic profiles of free and conjugated hGH, reported in figure 4.24, 
were determined in Sprague-Dawley rats. The rats were randomly divided into two 
groups of 3 animals per group. A dose of 0.1 mg/kg hGH (equiv.) was administered 
via tail vein. The hGH content in serum samples was quantified using the hGH 
ELISA kit. The pharmacokinetic data elaboration was performed by PkSolver 
program applying a bicompartmental model. 
The hGH level for native protein decreased rapidly at 30 min post-injection and 
fell to below the detection limit after 3 h. hGH-PLE50ald showed an higher 
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prolongation of the half-life, with detectable levels of hGH up to 6 h. Conjugation 
with PLE50ald led to an increase in blood residence time. Main pharmacokinetic 
parameters are shown in table 4.6. 
 
 
Figure 4.24: Pharmacokinetic best-fit profiles of hGH and hGH-PLE50ald. 
 
Table 4.6: Main pharmacokinetic parameters after i.v. administration in rats. 
Compounds t1/2 β (min) AUC(0→∞) (μg min/mL) Cl (mL/min) VD (mL) 
hGH 58.64 49.07 0.61 3.7 
hGH-PLE50ald 43.74 169.97 0.18 2.14 
 
 
4.3.4 Pharmacodynamic of hGH, hGH-PLE50ald, PEG-Gln141-hGH and 
PEG-Nter-hGH in hypophysectomized rats. 
 
The bioactivity of hGH-PLE50ald, PEG-Gln141-hGH and PEG-Nter-hGH was 
investigated in hypophysectomized rats by comparing the stimulation of somatic 
growth of conjugates and hGH. The free protein was administered for 6 days with a 
daily dose of 30 μg/rat while the conjugates were given as single injection of 180 
µg/rat at first day. PEG-Gln141-hGH and PEG-Nter-hGH achieved the same weight 
gain as hGH and hGH-PLE50ald demonstrated only a slight decrease in the potency 
respect to the other samples (Figure 4.25), thus confirming that the prolonged half 
lives of conjugates, lead to a great exposure of the protein achieving finally a good 
bioactive response even with a single dose per week. hGH, hGH-PLE50ald, PEG-
Gln141-hGH and PEG-Nter-hGH treatments promoted body weight gain with 
respect to the control (Table 4.7). 
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Figure 4.25: Weight gain in hypophysectomized rats given daily, via tail vein, injections of 
hGH (6 × 30 μg/rat) or one weekly dose of hGH-PLE50ald, PEG-Gln141-hGH or PEG-Nter-hGH 
(1 × 180 μg/rat, protein equivalent). 
 
The length of femur and the width of the tibial cortical bone tissue of diaphysis 
were determined in all animals at the end of the study. Compared to the control, the 
lengths of the femurs were significantly enhanced in hGH and hGH conjugates 
treated groups (Figure 4.26). In particular the increasing of bone length induced by 
PEG-Gln141-hGH and PEG-Nter-hGH was greater than one promoted by native 
protein and hGH-PLE50ald; 3.5% and 4.4% for conjugate respectively, vs. 2.2% and 
2.4% for hGH and hGH-PLE50ald. 
 
Figure 4.26: Femoral length gains in hypophysectomized rats given daily, via tail vein, 
injections of hGH (6 × 30 μg/rat) or one weekly dose of hGH-PLE50ald, PEG-Gln141-hGH or 
PEG-Nter-hGH (1 × 180 μg/rat, protein equivalent). 
 
The widths of tibial diaphysis demonstrated that the groups treated with hGH or 
hGH conjugates had a higher values with respect to the PBS-treated group. Also for 
this growth parameter, single injection of hGH-PLE50ald, PEG-Gln141-hGH or PEG-
Nter-hGH showed similar results with respect daily administrations of hGH. 
Representative stained sections of the tibial diaphysis are shown in Figure 4.27: the 
tibial compact bone of diaphysis is thicker in C (hGH-PLE50ald), D (PEG-Gln141-
hGH) and E (PEG-Nter-hGH) than A (vehicle) and B (hGH). The percentage growth 
of the width of the tibial cortical bone tissues was 8.1%, 11.6%, 13.4% and 2.1% for 
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hGH-PLE50ald, PEG-Gln141-hGH, PEG-Nter-hGH and hGH treated-groups, 
respectively.  
Cumulative body weight gain, femoral length and tibial diaphysis width 
measurements for the different groups are presented in Table 4.7. A weekly 
administration of hGH-PLE50ald, PEG-Gln141-hGH or PEG-Nter-hGH has shown 
similar bioactivities with respect to daily administrations of hGH, suggesting that the 
conjugates have prolonged the protein exposure to this receptor. The way in which 
the PEG chains are arranged around the protein is fundamental for the 
protein/receptor recognition process and, accordingly, also the site of polymer 
coupling. In this case, the results suggest that the steric entanglement of the polymer 
chain had a similar output for both conjugates. 
 
 
Figure 4.27: Representative stained sections of tibial diaphysis of hypophysectomized rats 
receiving, via tail vein, injections of A) vehicle every day; B) hGH 30 µg every day; C) hGH-
PLE50ald, D) PEG-Gln141-hGH and E) PEG-Nter-hGH 180 µg the first day. 
 
Table 4.7: Effects of every-day (ED) administration of vehicle solution and hGH for 6 d, and 
first-day (FD) administration of hGH-PLE50ald, PEG-Gln141-hGH and PEG-Nter-hGH on body 
weight gain, femoral length and tibial diaphyses width in hypophysectomized rats. 
Compound 
Dose and 
frequency 
Cumulative body 
weight gain (g) 
Femoral length 
(mm) 
Width of tibial 
diaphysis cortical 
bone (µm) 
Vehicle 150 µL × day -1.37 ± 1.28 22.90 ± 0.38 334.21 ± 38.64 
hGH 30 µg × day 7.98 ± 3.2 23.40 ± 0.37 341.19 ± 30.58 
hGH-PLE50ald 180 µg × week 5.9 ± 2.31 23.45 ± 0.28 361.21 ± 116.94 
PEG-Gln141-hGH 180 µg × week 8.4 ± 1.4 23.70 ± 0.31 373.08 ± 44.96 
PEG-Nter-hGH 180 µg × week 9.6 ± 2.49 23.92 ± 0.31 379.03 ± 25.43 
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4.4 SYNTHESIS AND CHARACTERIZATION OF PEG-KR14 
CONJUGATE 
 
 
4.4.1 Synthesis of KR14 
 
Before to synthesized the KR14, the azidoproline was prepared according to the 
procedure reported in section 3.6.1 and the yield was 79.5%. 
The peptide triazole KR14 was then synthesized by CEM microwave synthesis 
using Fmoc chemistry on a Rink amide resin at a 0.25 mM scale and after the 
assembling of the residues, it was undergone to N-terminal protection with the t-Boc 
group, click reaction in order to link the ethynylferrocene with a cycloaddition, 
cleavage from the resin and deprotection of the N-terminal. After the recovery, the 
crude peptide was dissolved in 50% ACN/H2O and purified by RP HPLC on a 
preparative C18 column. The final purified peptide were lyophilized and validated by 
MALDI-TOF mass spectrometry (Figure 4.28) 
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Figure 4.28: ESI-TOF mass spectrum of KR14. 
 
 
4.4.2 Synthesis of PEG-KR14 
 
KR14 was designed to contain a free thiol group at position 16. This single thiol 
group has been exploited to achieve selective PEGylation trough a Michael addition. 
This conjugation prevents the formation of peptide dimers. Moreover, the position 16 
is far from the pharmacophore that is formed by the first 7 amino acids. This 
approach should minimize the expected activity decrease of PT after PEGylation 
that, as known, is due to the detrimental effect of PEG steric entanglement on the 
binding kinetics. 
The conjugation reactions were monitored by SEC-HPLC. Figure 4.29 reported 
the time course of the conjugation of PEG-KR14. The disappearance over the time of 
the peak of free peptide (tR= 32.31 min) corresponded to the appearance of a new 
peak (tR= 19.37 min), in agreement with the formation of PEG-KR14 conjugate that 
has a higher hydrodynamic volume. The purification was carried out by dialysis and 
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was considered satisfactory when the peak of the starting peptide (tR around 31 min) 
had disappeared. Conjugation of PEG-Mal to peptide led to a reaction yield of about 
46%. After purification, the conjugate presented a content of free PEG of 36% and 
no free peptide. 
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Figure 4.29: Elution profile of KR14 and PEG-KR14. 
The monoconjugates were analyzed by MALDI-TOF mass spectrometry. The 
results showed that a monoPEGylated product was present with a MW centered at 
23815 Da corresponding approximately to the sum of one chain of PEG-Mal 
conjugated to KR14 (Figure 4.30). 
 
Figure 4.30: MALDI-TOF mass spectrum of PEG-KR14. 
 
 
4.4.3 Pharmacokinetic studies of KR14 and PEG-KR14 
 
The pharmacokinetic profiles of PEG-KR14 and free KR14 were evaluated in rats 
by labeling the peptide moiety with fluorescein. 
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4.4.3.1 Preparation of 5-FM-KR14 
 
KR14 was labeled with fluorescein exploiting the free thiol group. The reaction 
was conducted as reported in section 3.6.4.1 and was monitored and purified by RP-
HPLC (Figure 4.31). The product was then characterized by ESI-TOF analyses 
(Figure 4.32). 
 
 
 
Figure 4.31: Elution profile of 5-MF-KR14 on Agilent C18 (4.6 × 250 mm). The separation was 
achieved by a linear gradient of 20-70% acetonitrile containing 0.1% TFA over a 25 min period. The 
effluent from the column was monitored at 280 nm. 
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Figure 4.32: ESI-TOF mass spectrum of 5-FM-KR14. 
 
 
4.4.3.2 Preparation of FITC-PEG-KR14 
 
PEG-KR14 was labeled with fluorescein through the N-terminal amino group of 
the peptide. The reaction was conducted as reported in section 3.6.4.2 and the 
products was purified by dialysis and analyzed by SEC-HPLC (Figure 4.33). 
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Figure 4.33: Purification profile of FITC-PEG-KR14 on Agilent Zorbax GF-250 (4.6 × 250 mm). The 
effluent from the column was monitored at 494 nm. 
 
 
4.4.3.3 Pharmacokinetics 
 
The pharmacokinetic profiles of free and conjugated peptide were determined in 
Balb/C mice after i.v administration. 
As shown in figure 4.34, after administration, the plasma levels of PT decreased 
fast and it was not detectable (LOD = 0.8 ng/mL) after 150 min. On the contrary, 
PEG-KR14 showed a marked half-life prolongation with detectable levels after 360 
min. PEGylation greatly increased the blood residence time. In fact, the half-life of 
KR14 increased from 44.42 to 288.75 min after PEGylation (Table 4.8). Also the 
AUC of PEG-KR14 increased 8-9 fold with respect to free PT.  
 
 
 
Figure 4.34: Pharmacokinetic profile of native KR14 and PEG-KR14 in mice. 
 
Table 4.8: Main pharmacokinetic parameters of KR14 and PEG-KR14 after i.v. 
administration in mice. 
Compounds t1/2 α 
(min) 
t1/2 β 
(min) 
AUC(0→∞)  
(μg min/mL) 
Cl 
(mL/min) 
VD  
(mL) 
KR12 16 39.37 0.49 2.551 145.18 
KR14 22.95 44.42 0.34 3.850 246.82 
PEG-KR12 31.94 315 3.55 0.386 175.51 
PEG-KR14 21.79 288.75 3.08 0.462 192.36 
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4.4.4 Surface Plasmon Resonance competition experiments 
 
To compare the affinity of KR14 and PEG-KR14 for the gp120, surface plasmon 
resonance (SPR) competition experiments were conducted. The competition 
experiment provides the immobilization of the ligands (CD4 and 17b mAb, receptor 
and co-receptor) on a chip and the passage, over the surface, of a fixed solution of 
gp120 mixed to different amounts of native or modified peptide. 17b mAb is a co-
receptor surrogate that binds a gp120 epitope that is increased in exposure following 
CD4 binding. The experiment has allowed to evaluate the binding of KR14 and 
PEGylated PT to gp120 in the presence of CD4 and 17b mAb, and the inhibitory 
effects of peptide and conjugate on interactions of gp120 at its CD4 and co-receptor 
binding sites. 
In figure 4.35 is reported an example of sensorgram derived from a CD4 
competition experiment for KR14 and table 4.9 shows the IC50 values of KR14 and 
PEG-KR14 for the same experiment. Table 4.10 shows the IC50 values of KR14 and 
PEG-KR14 for the mAb 17b competition experiment. 
 
 
Figure 4.35: Inhibition of binding of gp120 to CD4 by KR14. CD4 was immobilized on the biosensor 
chip surface and gp120 was passed over the surfaces in solution with increasing concentrations of peptide. 
 
 
Table 4.9: Main IC50 values for KR14 and PEGKR14 measured by CD4 competion 
experiment. 
 
IC
50 
(nM) 
KR14 258.5 ± 14.7 
PEG-KR14 387.57 ± 29.4 
 
 
Table 4.10: Main IC50 values for KR14 and PEGKR14 measured by mAb 17b competion 
experiment. 
 
IC
50 
(nM) 
KR14 246.5 ± 20.1 
PEG-KR14 395.16 ± 8.6 
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The experiment has allowed to evaluate the binding of KR14 and PEGylated PT 
to gp120 in the presence of CD4 and 17b mAb, and the inhibitory effects of peptide 
and conjugate on interactions of gp120 at its CD4 and co-receptor binding sites. 
After PEGylation, no significant variations in the activity of the peptide were found, 
both for the CD4 and 17b mAb competition. Referring to IC50 values, PEG-KR14 
was only about 1.5, 1.6 fold less active than free peptide. These results indicated that, 
after PEGylation, the peptide retained a significant activity in inhibiting the 
interactions of gp120 at its CD4 and co-receptor binding sites. The preservation of 
peptide activity after PEGylation is a promising result because usually the coupling 
of a such high molecular weight PEG causes a great loss of the peptide/protein 
activity. 
  
 
 
 
 
 
 
 
 
5 DISCUSSION 
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In the last years PEGylation has become the leading approach for proteins and 
peptides delivery and, therefore, this technique had and will have also in the future a 
central role for the full exploitation of biologics. 
The work reported in this thesis is focused on the design and preparation of 
polymer conjugates of therapeutic proteins and peptides. These systems have been 
studied for the obtainment of an improved balance between the pharmacokinetic and 
the pharmacodynamic of a conjugated biologic and for the optimization of the 
polymeric carrier. Any new discovered protein coming, thanks to the completion of 
human genome project, nowadays, might represent a new target for highly specific 
therapies, or might even, itself, become a new drug. Therefore the demand of protein 
and peptide delivery systems is expected to increase in the future. As demonstration, 
the number of PEGylated products on the market is continuously increasing, together 
with the number of new conjugates entering clinical trials. 
This growing success, however, is not devoid of pitfalls, and often the therapeutic 
exploitation of a new protein or peptide is hampered by unexpected shortcomings. 
Among these potential limits it is possible to list: i) rapid renal clearance, ii) 
immunogenicity, iii) susceptibility to enzymatic degradation and iv) physical and 
chemical instabilities. In particular, a short half-life in blood is a significant problem 
because is reflected in frequent administration schedule of the biologic or in the 
injection of an high dose, to achieve the desired effect, thus also aggravating the side 
effects. The coupling of a polymeric carrier and in particular of PEG to a biologic 
drug, has demonstrated the advantage to overcome most of the aforementioned limits 
of biologics by acting on several aspects. For example, PEGylation reduces the rapid 
kidney clearance of a given protein or peptide by increasing their hydrodynamic 
volume, prevents immunogenicity and aggregation by shielding the protein surfaces 
and also increases the thermal stability. Although a reduction in biological potency is 
usual after PEGylation, due to the steric entanglement of polymer chains during 
recognition of the protein or the peptide with their targets, the advantages of this 
approach largely counterbalance this drawback. 
The studies of this PhD has been organized into three works. The first study 
focused in the conjugation of common non charged or new multicarboxylic PEGs to 
G-CSF, a therapeutic protein presently in clinical use. G-CSF is a hematopoietic 
growth factor of myeloid lineage, involved in the proliferation, differentiation, and 
survival of granulocytes (neutrophils, eosinophils, and basophils). The aim was to 
extend the PK profile of the protein with polyanionic PEG that should allow a better 
preservation of protein activity. 
The rationale of using multicarboxylic PEGs, in particular, lies in the recent 
understanding of the charge-selectivity concept of glomerular filtration. The idea is 
to exploit this concept to achieve further prolonged protein pharmacokinetics while 
reducing the possible impairment in protein pharmacodynamics caused by the steric 
hindrance of high-molecular weight PEGs. 
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The first part of the work was composed of two main sections: preparation of G-
CSF-PEG conjugates via mTGase-mediated PEGylation, with the subsequent 
characterization and stability analyses, and pharmacokinetic studies of the conjugates 
in rats. In fact it was of paramount relevance also to understand the role of 
multicorboxylic PEG on the stability and physic-chemical properties of a given 
protein. 
Four different PEGylated derivatives of G-CSF were prepared via mTGase-
mediated PEGylation. The PEGs used included two multicarboxylic and two neutral 
PEGs. Of the multicarboxylic PEGs the following derivatives were studied: 1) H2N-
PEG5k-(COOH)7 (MW 5717 Da ), a PEG-dendron obtained from a 
heterobifunctional PEG that was derivatized at one end with β-glutamic acid as 
branching units to provide 7 carboxyl groups, and with a primary amino group on the 
other end for enzyme-mediated protein conjugation, 2) H2N-PEG3.4k-b-PLE50 (MW 
11000 Da), a linear PEG of 3.4 kDa linked to a PLE of 50 L-glutamic acid units. 
Two neutral PEGs, mPEG5k-NH2 and mPEG20k-NH2, were also used to allow 
comparison of the pharmacokinetic profiles between the conjugates, thus enabling to 
assess the influence of negatively charged polymers on protein pharmacokinetics. 
The yields of reaction for negatively charged PEGs were even higher with respect to 
neutral PEGs. The results confirmed that the conjugates were pure and mono-
PEGylated as showed by SDS-PAGE and MALDI mass spectrometry. Circular 
dichroism was used to investigate the effect of this type of conjugation on the 
secondary structure of G-CSF. As the purification conditions may also affect the 
conformation of a protein, a G-CSF sample, purified under the same conditions of 
the conjugates, was also included in this study. CD investigation showed that there 
was no significant change in the secondary structure of G-CSF after PEGylation. 
Melting profiles, obtained by monitoring the protein unfolding as a function of 
temperature, revealed that the thermal stabilities of all conjugates were quite similar 
to each other and to that of G-CSF purified with the same conditions. However, they 
seemed to be less stable with respect to the native G-CSF. These findings suggested 
that the decrease in the stability of G-CSF after PEGylation may be due to the 
purification conditions or eventually to the different buffer, i.e. acetate pH 4.6 for 
native G-CSF and phosphate pH 7.4 for conjugates. Resolving this issue also by 
exploring more suitable purification conditions remains a future scope of this project. 
The pharmacokinetic studies of the native G-CSF and its PEGylated derivatives in 
rats showed, firstly, that the native G-CSF had an elimination half-life of 2.99 hours, 
in accordance with the data reported in literature and its plasma level fell below the 
detection limit after 7 hours. Conversely all PEGylated G-CSF derivatives showed 
prolonged half-lives (up to 11 hours), with detectable serum G-CSF levels even after 
24 hours, as well as markedly reduced clearance and volume of distribution. G-CSF-
PEG5k-(COOH)7 and G-CSF-PEG3.4k-b-PLE50, obtained with the multicarboxylate 
PEGs of 5717 Da and 11000 Da, showed half-lives comparable to that of G-CSF-
PEG20k, prepared with a neutral PEG of 20 kDa. 
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Based on these data, it can be proposed that the presence of negative charges on 
the polymer results in conjugates with an increased half-life, with respect to the 
conjugates obtained with neutral PEGs of similar molecular weights. Therefore, in 
order to significantly improve the pharmacokinetic profile of proteins, polyanionic 
PEGs with lower molecular weights than those required with neutral PEGs may be 
considered as protein carriers, thus reducing the typical steric hindrance of high 
molecular weight PEG that might impair the biological function of proteins. 
The second part of the PhD thesis focused on the comparison of the biological 
activity (stimulation of somatic growth) of three hGH conjugates differing for the 
polymeric carrier (multicarboxylic or neutral form) and for the site of polymer 
conjugation. hGH is a therapeutic protein involved in growth promotion, stimulation 
of protein synthesis, lipolysis and regulation of metabolic processes. The aim of this 
study was to evaluate if the protein stability and the protein/receptor recognition 
process were influenced by the site of conjugation of the polymer and to assess the 
impact of polyanionic carriers on the pharmacodynamic behaviour of the protein. 
Conjugation of the multicarboxylic polymer, poly(L-glutamic acid), resulted in an 
increase of the final negative charge of the conjugate. The rationale of the use of 
negatively charged polymers for protein delivery has been above reported. The 
possibility to obtain the same half-life prolongation with low molecolar weight 
negative polymer might allow: i) a faster diffusion of the conjugate into the tissues, 
thanks to the lower hydrodinamic volume of the polymer, ii) a better preservation of 
the binding affinity of the protein to its receptor, thanks to the lower steric hindrance 
provided by the polymer and iii) a decrease of protein aggregation due to charge 
repulsion. 
Two different site-specific mono-PEGylated forms of hGH were prepared 
exploiting an enzymatic PEGylation (PEG-Gln141-hGH) via transglutaminase 
(TGase) and a chemical N-terminal PEGylation (PEG-Nter-hGH) with neutral 20kDa 
PEGs. The enzymatic PEGylation was performed in presence of 50% of EtOH (v/v) 
in order to increase the selectivity of mTGase. Usually, only one or two glutamines, 
present in a highly flexible region, are substrate for the enzyme, but, it is known from 
literature that, incubating the protein in a proper water/organic co-solvent mixture, it 
is possible to increase the rigidity of the native protein, thus finally restricting the 
mTGase selectivity which need a glutamine inserted in a flexible bag for performing 
its activity. The chemical PEGylation was conducted in acidic conditions to direct 
the modification at the N-terminus, thanks to the lower pKa value of α-amino group 
with respect to the ε-amino groups. The conjugates were obtained with different 
yields: 40% for PEG-Gln141-hGH and 52% for PEG-Nter-hGH. The success of the 
synthesis was determined by RP and SEC-HPLC, MALDI-TOF mass spectrometry 
and SDS-PAGE. The conjugates were pure and mono-PEGylated. The sites of 
PEGylation were previously confirmed by our research group [Mero 2011 and 
Freitas 2013]. Far-UV CD spectra of native protein and PEG-hGH conjugates were 
compared and showed that both the N-terminus or the Gln141 PEGylation preserved 
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the protein’s secondary structures, as the profiles were superimposable with that of 
hGH. Thermal denaturation was carried out to investigated if the different 
PEGylation site caused a difference in the thermal stability of the two conjugates, by 
evaluating the changes in the ellipticity at 208 nm. The melting temperature 
calculated for native protein and PEG-Gln141-hGH were 82°C and 83.8°C, 
respectively. PEG-Nter-hGH displayed a higher thermal stability, with a melting 
temperature of 86.1°C. 
Reversibility of the thermal unfolding was determined by measuring the recovery 
of the CD signal upon heating at 95°C and cooling at 20°C the hGH and PEGylated 
hGH solutions. The CD spectra at 95°C showed the disappearance of the bands at 
222 and 208 nm, characteristic of hGH α-helical structure in physiological 
conditions. This means that at 95°C the three samples lost their native α-helical 
structure but the conjugates, even at such high temperature, tend to preserve a certain 
percentage of α-helical structure with respect to hGH. Moreover the transition was 
reversible and partially reversible for PEG-Nter-hGH and PEG-Gln141-hGH, 
respectively, opposing to the permanent denaturation of hGH and in particular, PEG-
Nter-hGH showed a total recovery of the native α-helical structure. These results 
indicated that PEGylation increased thermal stability of hGH and favored the protein 
refolding, but for a complete recovery, the site of PEG conjugation is relevant. 
Probably this behavior depends on the way the PEG chain is arranged around the 
protein, likely in the case of protein N-terminus conjugation, the polymer is more 
effective in stabilizing the protein. 
The third site-specific monoconjugate of hGH was prepared by chemical N-
terminal conjugation via aldehyde, using poly(L-glutamic acid) (PLE). PLE is 
obtained by polymerization of β-glutamic acid, therefore is biodegradable and non-
toxic. It has a linear structure with a pending ϒ-carboxyl group for each repeated 
glutamic acid unit, conferring the polymer a polyanionic characteristic. In this case a 
PLE with 50 glutamic acid units and with an aldehyde function at one end (PLE50ald) 
was chosen. After the removal of the protecting acetal group from PLE50ald, several 
reaction conditions were tested to find out the most efficient. Reaction buffer, 
polymer molar excess and incubation temperature were varied. Phosphate buffer, pH 
6.2 was found to be the buffer in which the yields of reaction were the highest. 
Moreover, the increase of the polymer molar excess and also of the temperature led 
to an increase in the biconjugate formation, suggesting to performed the reaction 
using 5 equivalents of polymer and at 35°C. The conjugate hGH-PLE50ald was 
obtained with a yield of 55%. The success of the synthesis was determined by SEC-
HPLC, MALDI-TOF mass spectrometry and SDS-PAGE. The conjugates were pure 
and formed by one chain of polymer attached to the protein. Far-UV CD spectra 
showed that hGH still maintained the native secondary structure thus indicating that 
the conjugation with PLE50ald preserved the protein conformation. 
Pharmacokinetics of the native hGH and hGH-PLE50ald in rats, and subsequent 
evaluation of their pharmacokinetic profiles, showed a rapidly decrease, post-
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injection, of the hGH level for native protein while hGH-PLE50ald demonstrated an 
higher prolongation of the half-life, with detectable levels of hGH up to 6 h, 
indicating that also the conjugation with PLE50ald led to an increase in blood 
residence time. 
Pharmacodynamics allowed to compared the bioactivity of hGH, hGH-PLE50ald, 
PEG-Gln141-hGH and PEG-Nter-hGH in the stimulation of somatic growth in 
hypophysectomized rats, unable to produce somatotropin. In particular, daily 
administrations (dose of 30 μg/rat) of hGH were compared to single injections (dose 
180 µg/rat) at first day of conjugates. In the weight gain test, the body weight was 
measured every day for 6 days. PEG-Gln141-hGH and PEG-Nter-hGH were found 
to achieve the same weight gain as hGH and hGH-PLE50ald demonstrated only a 
slight decrease in the potency respect to the other samples. This confirmed that the 
prolonged half lives of conjugates, lead to a great exposure of the protein reaching 
finally a good bioactive response even with a single dose per week. At day 7, the 
mean of femur lengths was also determined. Compared to the control, the lengths of 
the femurs were significantly enhanced in hGH and in all hGH conjugates treated 
groups. In particular the increase of bone length induced by PEG-Gln141-hGH and 
PEG-Nter-hGH was greater than one promoted by native protein and hGH-PLE50ald; 
3.5% and 4.4% for conjugate respectively, vs. 2.2% and 2.4% for hGH and hGH-
PLEald50. Also the evaluation of the widths of tibial diaphysis demonstrated that the 
groups treated with hGH or hGH conjugates had a higher values with respect to the 
PBS-treated group. Single injection of hGH-PLE50ald, PEG-Gln141-hGH or PEG-
Nter-hGH showed similar results with respect daily administrations of hGH. The 
percentage growth of the width of the tibial cortical bone tissues was 8.1%, 11.6%, 
13.4% and 2.1% for hGH-PLE50ald, PEG-Gln141-hGH, PEG-Nter-hGH and hGH 
treated-groups, respectively. 
As conclusion of this study, it is possible to assert that: i) a weekly administration 
of hGH-PLE50ald, PEG-Gln141-hGH or PEG-Nter-hGH had similar bioactivities with 
respect to daily administrations of hGH; ii) the conjugates have prolonged the protein 
exposure to the receptor, both in case of neutral and polyanionic conjugation. hGH-
PLE50ald had only a slight decrease in the performance with respect the hGH-
PEG20kDa conjugates but comparable to that of daily administration of the native 
protein; iii) the N-terminal PEGylation yielded a conjugate with an higher thermal 
stability and, in particular, it was able to recover the secondary structure after 
thermal denaturation, but in this case, the results suggested that the steric 
entanglement of the polymer chain had a similar output for both the conjugation 
strategies. 
The way in which the PEG chains are arranged around the protein is fundamental 
for the protein/receptor recognition process and, accordingly, also the site of polymer 
coupling. This point is crucial because the protein function is known to be strictly 
related to the preservation of its native structure. Therefore, the possibility to obtain 
by PEGylation more stable proteins or even proteins that can refold spontaneously 
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after denaturation might represent an important achievement. Interestingly, we have 
also demonstrated that this stabilization is depending on the site of polymer coupling, 
this suggesting that PEG might have an active role in promoting the refolding. 
The third part of this PhD thesis has dealt with: synthesis and characterization of 
KR14 peptide and its conjugation with PEG20kDa-Mal, SPR affinity binding 
experiments and pharmacokinetic studies of the conjugate in mice. Peptide triazole 
KR14 bind to the envelope glycoprotein gp120 of HIV-1 with 1:1 stoichiometry 
inhibiting the interactions at both the CD4 and co-receptor binding sites and is 
broadly active in neutralizing cell infection by virus subtypes from all major clades. 
For the synthesis of KR14, azidoproline was previously prepared and obtained with a 
yield of 79.5%. Then KR14 was synthesized using a CEM microwave synthesizer, 
N-terminal protected with the t-Boc group, the ethynylferrocene was linked by click 
reaction, it was cleaved from the resin and deprotected at the N-terminus. The final 
purified peptide was lyophilized and validated by MALDI-TOF mass spectrometry, 
revealing a MW of 2126 Da. KR14 was designed to contain a free thiol group at 
position 16. This single thiol group has been exploited to achieve selective 
PEGylation through the maleimide of the 20 kDa PEG. This conjugation prevents the 
formation of the peptide dimer. The position 16 is also far from the pharmacophore 
that is formed by the triplet Ile-Azp-Trp (positions 5, 6 and 7). This approach should 
minimize the expected activity decrease of the peptide after PEGylation that, as 
known, is due to the detrimental effect of PEG steric entanglement on the binding 
kinetics. Conjugation of PEG-Mal to peptide led to a reaction yield of 46%. The 
monoconjugate was analyzed by SEC-HPLC and MALDI-TOF mass spectrometry. 
The results showed that a monoPEGylated product was present with a MW centered 
at 23815 Da corresponding approximately to the sum of one chain of PEG-Mal (MW 
21000 Da) with one molecule of KR14. 
The pharmacokinetic profiles of PEG-KR14 and free KR14 were evaluated in 
mice, after the labelling with fluorescein. After administration, the plasma levels of 
KR14 decreased fast and it was not detectable after 150 min. PEGylation greatly 
increased the blood residence time. In fact, the half-life of KR14 increased from 
44.42 to 288.75 min after PEGylation and also the AUC of PEGylated PT increased 
8-9 fold with respect to free peptide.  
To compare the affinity of KR14 and PEG-KR14 for the gp120, surface plasmon 
resonance (SPR) competition experiments were conducted. The competition 
experiment provides the immobilization of the ligands (CD4 and 17b mAb, receptor 
and co-receptor) on a chip and the passage, over the surface, of a fixed solution of 
gp120 mixed to different amounts of native or modified peptide. 17b mAb is a co-
receptor surrogate that binds a gp120 epitope that is increased in exposure following 
CD4 binding. The experiment has allowed to evaluate the binding of KR14 and 
PEGylated KR14 to gp120 in the presence of CD4 and 17b mAb, and the inhibitory 
effects of peptide and conjugate on interactions of gp120 at its CD4 and co-receptor 
binding sites. After PEGylation, no significant variations in the activity of the 
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peptide were found, both for the CD4 and 17b mAb competition. The CD4 
competition IC50 values for KR14 and PEG-KR14 were, respectively, 258.5 ± 14.7 
nM and 387.57 ± 29.4 nM, while the IC50 calculated after the 17b mAb competiton 
experiment were 246.5 ± 20.1 nM for the peptide and 395.16 ± 8.6 nM for the 
PEGylated KR14. PEG-KR14 was only about 1.5, 1.6 fold less active than free 
peptide. This results indicated that, after PEGylation, the peptide retained a 
significant activity in inhibiting the interactions of gp120 at its CD4 and co-receptor 
binding sites. The preservation of peptide activity after the PEGylation, is a 
promising result because usually the coupling of a such high molecular weight PEG 
causes a great loss of the peptide/protein activity. 
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